Whipworm and roundworm infections

Kathryn J. Else¹✉, Jennifer Keiser^{2,3}, Celia V. Holland⁴, Richard K. Grencis¹, David B. Sattelle⁵, Ricardo T. Fujiwara⁶, Lilian L. Bueno⁶, Samuel O. Asaolu⁷, Oluyomi A. Sowemimo⁷ and Philip J. Cooper^{8,9}

Abstract | Trichuriasis and ascariasis are neglected tropical diseases caused by the gastrointestinal dwelling nematodes *Trichuris trichiura* (a whipworm) and *Ascaris lumbricoides* (a roundworm), respectively. Both parasites are staggeringly prevalent, particularly in tropical and subtropical areas, and are associated with substantial morbidity. Infection is initiated by ingestion of infective eggs, which hatch in the intestine. Thereafter, *T. trichiura* larvae moult within intestinal epithelial cells, with adult worms embedded in a partially intracellular niche in the large intestine, whereas *A. lumbricoides* larvae penetrate the gut mucosa and migrate through the liver and lungs before returning to the lumen of the small intestine, where adult worms dwell. Both species elicit type 2 anti-parasite immunity. Diagnosis is typically based on clinical presentation (gastrointestinal symptoms and inflammation) and the detection of eggs or parasite DNA in the faeces. Prevention and treatment strategies rely on periodic mass drug administration (generally with albendazole or mebendazole) to at-risk populations and improvements in water, sanitation and hygiene. The effectiveness of drug treatment is very high for *A. lumbricoides* infections, whereas cure rates for *T. trichiura* infections are low. Novel anthelmintic drugs are needed, together with vaccine development and tools for diagnosis and assessment of parasite control in the field.

Whipworms are large-intestinal nematode parasites of mammals. The scientific name for whipworms is *Trichuris* (which means ‘hair tail’), a name applied by Johann Georg Roederer in 1761, who mistook the thin front end for the tail. Over 70 *Trichuris* spp. are recognized, including the medically important human parasite *Trichuris trichiura* (the aetiological agent of trichuriasis) and the pig whipworm *Trichuris suis*. Whipworms have been associated with humans for over 8,000 years, as evidenced by the presence of *T. trichiura* eggs in coprolites (fossilized faeces) found in both Old World and New World archaeological sites^{1–3}. Roundworms (*Ascaris* spp.) are also intestinal nematodes, but, unlike whipworms, they dwell in the small intestine. *Ascaris lumbricoides* (first described by Carl Linnaeus in 1758) is the causative agent of the human disease ascariasis. In contrast to whipworms, the genus *Ascaris* differs from the genus *Trichuris* in that only one other *Ascaris* species has been described — *Ascaris suum*, a ubiquitous pathogen of pigs. After considerable debate as to whether these two ascarids are in fact distinct species, the current opinion is that they are two species, closely related at the phylogenetic level but reproductively isolated (that is, they are unable to interbreed successfully)⁴. Like *T. trichiura*, *A. lumbricoides* has a long association with its human host, with eggs detected in embalming material from over 7,000 years ago⁵ (FIG. 1).

Both *T. trichiura* and *A. lumbricoides* are highly prevalent helminths (common name for parasitic worms)^{6,7}. The infections occur by ingestion of embryonated (containing an embryo) eggs through contaminated soil or food. Both parasites contribute to chronic, long-term nutritional morbidity and affect cognitive development, although there is less evidence supporting this latter effect. Acute complications associated with *A. lumbricoides* infections of heavy intensity (that is, with a high worm burden) are intestinal obstruction and biliary ascariasis, whereas complications of *T. trichiura* infections include *Trichuris* dysentery syndrome (TDS) and rectal prolapse. The main approach to infection control is large-scale provision of anthelmintic treatment to children and girls and women of reproductive age, with accompanying improvements in access to clean water and sanitation, to reduce worm burden-associated morbidity⁸. Whilst largely effective against ascariasis, mass drug administration (MDA) programmes have been substantially less so against trichuriasis, particularly in sub-Saharan Africa⁹.

In this Primer, we provide a current view of both *T. trichiura* and *A. lumbricoides* infections epidemiology, disease mechanisms, diagnosis, screening and prevention. We also review current management strategies and consider key research areas that may lead to improved control of these two important neglected tropical

✉e-mail: Kathryn.else@manchester.ac.uk
<https://doi.org/10.1038/s41572-020-0171-3>

Author addresses

¹Lydia Becker Institute for Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

²Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.

³University of Basel, Basel, Switzerland.

⁴Department of Zoology, School of Natural Sciences, Trinity College Dublin, Dublin, Ireland.

⁵Centre for Respiratory Biology, UCL Respiratory, Rayne Building, University College London, London, UK.

⁶Department of Parasitology, Institute of Biological Sciences (ICB), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

⁷Department of Zoology, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.

⁸Institute of Infection and Immunity, St George's University of London, London, UK.

⁹Facultad de Ciencias Medicas, de la Salud y la Vida, Universidad Internacional del Ecuador, Quito, Ecuador.

diseases. Further, we compare and contrast *Trichuris* spp. and *Ascaris* spp. infections, which, despite the parasites sharing several traits, differ in important areas, with relevant consequences for control strategies.

Epidemiology

T. trichiura and *A. lumbricoides* infections are highly prevalent worldwide, with estimates of 465 and 819 million affected humans, respectively, in 2010 (REFS^{6,10}). Owing to infection control efforts, the overall prevalence of ascariasis was estimated to decline by 10% between 2005 and 2015, whereas trichuriasis prevalence declined by only 2%¹⁰. Although the oral–faecal route of infection is the same for both parasites, their geographical distributions do not perfectly overlap (FIG. 2), perhaps owing to spatial factors such as temperature, humidity and soil type; however, it is not known why the distributions diverge in some specific areas. In the endemic areas where the distributions overlap, co-infections frequently occur and probably result in exacerbation of morbidity and heavy infection intensities^{11–15}. Co-infections often affect children and are generally underdiagnosed, as they are associated with non-specific gastrointestinal symptoms. Morbidity is most likely to occur among children with moderate to heavy infection intensities and is attributed to chronic effects on nutrition and growth. There are limited data to quantify the frequency of complications of trichuriasis and ascariasis, but, in 2017, the estimated number of deaths worldwide attributable to ascariasis was 3,205, whereas no deaths were considered attributable to trichuriasis¹⁶.

Trichuris trichiura

T. trichiura infections are most frequent in warm and moist conditions in tropical and sub-tropical regions. Although zoonotic infections with other *Trichiura* spp. such as *T. suis* (from pigs) and *Trichiura vulpis* (from dogs) have been reported in humans, these parasites generally cause attenuated infections and rarely develop to sexual maturity in humans. Geographical information system tools that enable prediction of regions that are permissive for transmission, on the basis of spatial information on temperature, humidity and population density, have been used to estimate the geographical distribution of *T. trichiura* (FIG. 2). Transmission requires embryonation of *T. trichiura* eggs in the environment,

and whilst eggs can survive temperatures below freezing, they will not embryonate in freezing conditions or if temperatures exceed 37°C (REFS^{17,18}).

Under experimental conditions, humans can become infected with the pig whipworm *T. suis*¹⁷. These infections seem to only establish temporarily¹⁹, although one study²⁰ found the maturation of *T. suis* to fecund, fully grown adult worms in a volunteer. Similarly, *T. trichiura* can be established in pigs, but the parasites do not persist in this host¹⁷. Further, data indicate that the taxonomic, population and phylogenetic structure of *T. trichiura* is complex²¹. Altogether, these data suggest that *T. trichiura* is not a single multi-host species but a series of lineages, some of which can infect multiple mammalian host species.

Prevalence. Human trichuriasis is a classic disease of poverty, in which a lack of education and access to sanitation and clean water within an ecologically permissive environment favours infection transmission. In such environments, community prevalence of infections can be >90%, and infections can particularly affect children of 5–15 years of age, who have the greatest parasite burdens²². Age-prevalence profiles are concave; prevalence peaks at an earlier age in areas of more-intense transmission than in areas where transmission is not as intense and probably relates to exposure risk (ingestion of eggs from a faecally contaminated environment). An age-dependent decline in prevalence is often observed in children of >15 years of age and in adults, probably owing to reduced exposure and possible age-acquired immunity.

Treatment of school-age children is considered a cost-effective strategy for the control of *T. trichiura* infection in communities in endemic areas: by cutting the number of infections in the primary parasite reservoir²³, transmission within communities is reduced. Temporal improvements in economic and environmental conditions, coupled with increased access to periodic chemotherapy for school-age children, have led to substantial declines in prevalence and intensity of infection in Asia since the year 2000, particularly in China and Indonesia⁶. Although similar declines have not been observed in Latin American and sub-Saharan African regions^{6,24}, declines in the numbers of children with moderate to heavy infection intensities (the population most at risk of severe disease) have been observed in almost all settings in which school-age children have received repeated preventive chemotherapy²⁵.

Risk factors. The risk of *T. trichiura* infection is not uniform within populations in endemic areas: a small proportion of infected individuals (typically <10% in high-prevalence populations), generally children of 2–15 years of age, harbour most adult worms, whereas the remaining infected children and adults harbour few adult worms²³. Such aggregated distributions of adult worms (which may survive for 1–8 years in the human intestine²⁶) within communities in endemic areas are typical of soil-transmitted helminths (STHs). There is evidence from some, but not all, epidemiological studies of an increased susceptibility to *T. trichiura* infection among some groups of individuals — for example,

Fig. 1 | **Soil-transmitted helminth infections.** **a** | Helminth is an umbrella term for human multicellular endoparasites; most of these worms belong to the Nematoda and the Platyhelminthes phyla. A third phylum of parasitic worms exists: the Acanthocephala phylum; however, these worms very rarely infect humans, who are occasional accidental hosts. The Trematoda and Cestoda are classes of platyhelminths, whereas the so-called soil-transmitted helminths are found within the Nematoda. Examples of genera found within each phylum are included. **b** | Main similarities and differences between *Trichuris trichiura* and *Ascaris lumbricoides* parasites.

previously infected individuals are more likely to become reinfected after chemotherapy than uninfected individuals²⁷. Individual susceptibility may be determined by one or more behavioural, environmental, genetic and immunological factors²⁷. Further, individuals with heavy infection intensities tend to be those who re-acquire the highest parasite burdens following treatment^{18,27,28}. *T. trichiura* clustered within families in rural China²⁹, and a linkage analysis in Nepal identified two quantitative trait loci on chromosomes 9 and 18, respectively, that were associated with susceptibility to infection³⁰, although the contributing genes at these loci remain unknown. Finally, a study in Brazil showed that susceptibility to *T. trichiura* infection was associated with polymorphisms in *TGFB1* (REF.³¹).

Ascaris lumbricoides

Globally, *A. lumbricoides* was estimated to infect 819 million people in 2010 (REFS^{6,32}), with a similar geographical distribution in tropical and subtropical areas to that observed for trichuriasis (FIG. 2). Experimental and molecular evidence of possible cross-transmission indicates that humans can be infected by *A. suum*^{33–35}, and pigs can harbour *A. lumbricoides*³⁵. These data suggest that pigs might act as a potential reservoir of infection for humans and, more importantly, might point out a possible role of zoonotic infection by *A. suum* in humans³⁶. The zoonotic potential of both *A. suum* and *T. suis* has been reviewed³⁷.

Prevalence and risk factors. Ascariasis is also associated with poverty, and hence the lack of proper sanitary infrastructure and poor socio-economic conditions favour the transmission of the parasite^{38,39}. Overall, an over-dispersed frequency distribution⁴⁰ is observed, with most individuals harbouring a low to moderate parasite burden and few hosts with heavy infection intensities. Socio-economic factors, such as poor housing⁴¹ and deficiency in hygiene practices⁴², influence the intensity of infection. The infection intensities observed in adults are often lighter than those found in children⁴³, and this observation might suggest a behaviour-mediated reduction

of exposure or the development of acquired immunity with chronic exposure to the parasite. However, whereas experimental data in mice demonstrate a reduction in parasite burden after repeated exposure to *A. suum*⁴⁴, the over-dispersed frequency distribution in humans is recorded in all age groups, indicating that neither age nor immunity are the primary determinants of variability in infection intensity.

Environmental and behavioural features⁴⁵, as well as a host's genetics and immunity^{46–50}, are important determinants of infection status⁵¹. Predisposition (that is, reinfection with similar or higher worm burdens than pretreatment burdens) is also an epidemiological phenomenon observed in human ascariasis⁴³, as well as in trichuriasis. In a systematic review²⁷, children were found to show greater predisposition to *A. lumbricoides* infection than adults, and girls were more predisposed than boys. Although the mechanisms that determine predisposition are not fully elucidated, exposure to infection and host susceptibility are likely to be important.

Mechanisms/pathophysiology

Studies on immunity to human whipworm and roundworm infections have generated interesting immune correlates with resistance to reinfection; however, it is through the use of animal models, and particularly the laboratory mouse, that understanding of pathological mechanisms has been gained. Novel imaging tools are beginning to provide unique insights into both host pathology and parasite behaviour^{52,53}. Current knowledge on human infection, followed by insights from animal models, are discussed below, including, where possible, reflections on how findings in animal models fit with the human disease.

Trichuris spp.

The life cycles of all *Trichuris* spp. are similar (FIG. 3). After the ingestion of food or water contaminated with soil containing embryonated eggs, the eggs hatch in the large intestine (caecum and/or proximal colon); in the mouse, hatching of *Trichuris muris* eggs is triggered by the presence of bacteria, and probably similar

Fig. 2 | **Prevalence of *Trichuris trichiura* and *Ascaris lumbricoides* infections in 2010.** Distribution of *Trichuris trichiura* infection (part **a**) and *Ascaris lumbricoides* infection (part **b**), estimated on the basis of geostatistical models for sub-Saharan Africa and available empirical information for all other regions. *T. trichiura* infection may also occur in high-income regions, in populations living in conditions of poverty (such as aboriginal populations in Australia³⁰⁹) or among migrants⁷. In migrants, most infections are acquired elsewhere, as adequate hygiene and sanitation in most high-income regions provide limited opportunities for transmission. Adapted from REF.⁶, CC BY 2.0 (<https://creativecommons.org/licenses/by/2.0/>).

bacterial cues are applicable to egg hatching in other *Trichuris* spp.⁵⁴. First stage (L1) larvae are released and penetrate the epithelial cells at the crypt base, where they create and inhabit an intracellular niche formed by a multicellular epithelial ‘tunnel’, the biology of which is unknown⁵⁵. In this niche, L1 larvae grow and moult through the larval (L2, L3 and L4) and adult stages; timings of these moults are defined in the mouse model⁵⁶, but the equivalent timings in humans are unclear. By the L3 stage, the parasite is no longer fully intracellular. Thus, its posterior end protrudes into the gut lumen, whilst its long thin anterior end, which contains the stichosome (a modified oesophagus comprising multiple

cells (stichocytes) that duct into the oesophageal lumen), remains embedded within a syncytial tunnel of modified host epithelial cells, without substantially compromising the integrity of the gut barrier. The pre-patent period (that is, the time from infection to egg production) is ~33–35 days in mice: adult male and female *T. muris* worms emerge around 32 days after infection, with fertilized adult females releasing 2,000 to 8,000 eggs per day⁵⁷. Eggs of *Trichuris* spp. are expelled with host faeces unembryonated and, therefore, in a non-infective state. Embryonation takes 2–4 weeks, depending on environmental conditions¹⁷; by then, the L1 larva has developed within the egg and the egg is now infective.

The life cycle of *T. trichiura* is similar to that of *T. muris*, although the timings of moults may differ. Thus, in humans, patent infections develop in 2–3 months, and adult worms, measuring 3–5 cm, may survive for 1–8 years in the human intestine²⁶. Throughout their life cycle in the murine, porcine and human hosts, *Trichuris* spp. excrete and secrete a variety of parasite-derived molecules that interact with the host environment. Some molecules are antigenic and some are immunomodulatory^{58–60}, but the functions of most are still to be determined. A better understanding of the host–parasite relationship is likely to support the development of new therapeutics (see Outlook).

Human trichuriasis: the evidence for type 2 acquired immunity to infection. Studying immunity to human trichuriasis is fraught with difficulty, with challenges including genetic heterogeneity, undefined infection

history and exposure, and polyparasitism. Nevertheless, comprehensive cross-sectional serological field studies point clearly to a positive correlation between high anti-*T. trichiura* IgE levels and decreasing infection intensity⁶¹, with IgE representing an antibody isotype controlled by type 2 immunity responses. There are no analyses of type 1 and type 2 cytokines released by peripheral blood leukocytes isolated from humans infected solely with *T. trichiura* and re-stimulated in vitro, as polyparasitism is usual in populations in endemic areas. However, data from populations infected with more than one species of gastrointestinal nematodes including *T. trichiura* strongly support the hypothesis that these infections induce type 2 immunity and regulatory responses⁶² and that acquired immunity requires type 2 protective immune responses that develop slowly after years, if not decades, of exposure⁶³. Single-subject self-infection studies have contributed to our understanding of how

Fig. 3 | Life cycles of *Trichuris trichiura* and *Ascaris lumbricoides*. Both *Trichuris trichiura* and *Ascaris lumbricoides* infections are initiated by the oral ingestion of embryonated (infective) eggs. *T. trichiura* eggs hatch in the large intestine in response to molecular signals from bacteria. The first stage L1 larvae burrow into epithelial cells lining the crypts, and in this intracellular niche they grow and moult through to the adult stage. Thus, unlike *A. lumbricoides*, *T. trichiura* is an entirely enteric parasite. *A. lumbricoides* eggs hatch and release L3 larvae, covered by the L2 cuticle. Although the site of egg hatching has been a topic of some discussion, the current evidence points to the large intestine. L3 larvae penetrate the caecal and proximal colon mucosa and undergo a hepato-tracheal migration. L3 larvae first migrate to the liver, where the L2 cuticle is shed and further larval growth occurs.

Subsequently, larvae advance to the lungs, penetrate the alveolar spaces and move to the pharynx, from where they are coughed up and swallowed. In the small intestine, the now L4 larvae undergo a final moult (L5) and develop to adulthood. Sexually mature male and female *T. trichiura* and *A. lumbricoides* worms mate, and female worms produce unembryonated eggs that are shed in the faeces, where they develop to infectivity under appropriate conditions of temperature and moisture. Images of *Ascaris suum* larvae and larvae in lung (steps 2 and 4) courtesy of C. Holland. *A. suum* larva in liver (step 3) is adapted from REF.³¹⁰, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>). Images of adult *T. muris* (step 6) and *T. muris* eggs (steps 7 and 8) courtesy of R. Forman, University of Manchester, UK. Images of *A. lumbricoides* eggs (steps 7 and 8) courtesy of G. Deslyper, Trinity College Dublin, Ireland.

T. trichiura modulates human immunity: a longitudinal analysis of T cell subsets in mucosal biopsy samples and peripheral blood revealed a mixed mucosal T cell response (type 1 T helper (T_H1), T_H2, T_H17 and regulatory T (T_{reg}) cells), whilst circulating T helper cells became predominantly T_H2 cells⁶⁴. A second such study revealed an amelioration of the symptoms of colitis following *T. trichiura* infection, probably through improved T_H2 cell-mediated and IL-22-mediated barrier function⁶⁵.

Insights from animal models — type 2 immunity. Preclinical models have enabled us to delve more deeply into both the underlying cellular regulatory mechanisms that control resistance and susceptibility to infection and the effector mechanisms that eliminate the parasite. Although we focus on the *T. muris* mouse model of human trichuriasis, *T. suis* in pigs has also generated important data that reveal commonalities in type 2 immunity between mouse, human and pig⁶⁶.

T. muris is the natural whipworm of mice and is genetically and antigenically similar to *T. trichiura*; these two species also show similar epidemiological patterns in their respective hosts. The importance of type 2 immunity in resistance to infection has been unequivocally demonstrated by many different research laboratories^{67–70}, and research now focuses on untangling the contributions of cellular subsets^{68,71,72}. An emerging concept is that the relevance of different cell types in promoting type 2 immunity is context dependent; thus, cellular contributions that are essential in one strain of mouse become redundant in a different strain or when the cytokine balance is artificially manipulated^{73,74}, with important implications for translation of these findings to humans. One burning question is how protective type 2 responses develop (BOX 1); answers to this question might inform smart vaccine development in the future.

Box 1 | How do type 2 immune responses develop?

Although several cell types (for example, innate lymphoid cells, B cells and macrophages) possess MHC II and can present antigens to CD4⁺ T cells (that is, naive T helper (T_H) cells that have not yet differentiated into a T_H cell subtype), their *in vivo* contribution in murine trichuriasis is not fully defined. By contrast, dendritic cells (DCs) are potent antigen-presenting cells that play a key part in *Trichuris muris* infections in the mouse. Different subsets of DCs exist, with the IRF4⁺CD11c⁺CD11b⁺ DCs being the potent drivers of type 2 immunity after *T. muris* infection and IRF8⁺CD103⁺ DCs being associated with type 1 immunity and, therefore, chronic infection^{314,315}. How these subsets have compartmentalized roles is unclear, but mechanisms are probably mediated by both cell-intrinsic factors and external signals. For example, if the cellular phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (also known as SHIP1) is deleted specifically from DCs, *T. muris* expulsion is impaired³¹⁶. Further, different DC subsets may express different levels of cytokine receptors and, therefore, respond differently to stimulation by the family of alarmin cytokines (for example, IL-25, IL-33 and thymic stromal lymphopoietin (TSLP)) towards a type 2-promoting phenotype. Raising IL-25 or IL-33 levels in normally susceptible mice promotes resistance to *T. muris* infection³¹⁷, and blocking TSLP signalling in normally resistant mice delays worm expulsion³¹⁸. Other evidence implicating DCs as key players in the development of type 2 immunity comes from circadian studies, in which the DC circadian clock affected, at least in part, the outcome of *T. muris* infection³¹⁹. Mice infected in the morning were more resistant to infection than mice infected at night. This time-of-day dependency in resistance to infection does not occur in transgenic mice in which DCs lack a core clock gene; the hypothesized mechanism is a circadian regulation of levels of type 1 immunity-promoting cytokines.

The potential immune regulatory effects of *Trichuris* spp. on inflammation in the large intestine⁶⁵ have formed the basis of clinical trials using the pig whipworm *T. suis* (which causes an infection that generally does not persist beyond 6 weeks in the human intestine) to treat inflammatory diseases such as inflammatory bowel disease (IBD). To date, trials in which humans have orally ingested *T. suis* ova have shown no statistically significant benefits to patients with IBD^{75–77}. Therapy with *T. suis* ova has also been evaluated in clinical trials in patients with several other inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis and food allergy, but none has shown clear clinical benefit^{78,79}.

Insights from animal models — type 2 immunity-controlled effector mechanism. Mouse models also provide data on how T_H2 cells stimulate worm expulsion (FIG. 4). Arguably, the effector mechanism supported by the largest amount of evidence is the role of goblet cells and mucus. Studies in mucin-deficient mouse strains^{80,81} have shown that mucin 2 and mucin 5, subtypes A and C are important in resistance to *T. muris*, probably via direct interactions with the parasite in the gut. The presence of mucin 2-degrading enzymes in the *Trichuris* spp. genome also supports an anthelmintic role for mucin⁸². Complementing a mucus-based effector mechanism, type 2 immunity cytokines can stimulate intestinal muscle contraction in the context of *T. muris* infection, and this increased contractility is associated with an acceleration of worm clearance⁸³. Whereas increases in mucus production and contraction of gut muscles may be common host responses to most gastrointestinal helminths, regulation of epithelial cell turnover may be an effector mechanism specific to *Trichuris* spp. For example, the type 2 immunity cytokine IL-13 can increase the rate of epithelial turnover, thereby displacing the parasite from its intracellular niche⁸⁴. Whether these effector mechanisms also apply to human trichuriasis is difficult to establish, although it is probable. Murine and human gastrointestinal helminth infections drive strong IgE responses, mostly non-specific⁸⁵. As mentioned above, the levels of IgE antibodies specific to *T. trichiura* negatively correlate with worm burden in humans. Thus, individuals with light infection intensities have significantly higher anti-*T. trichiura*-specific IgE levels than those observed in individuals with heavy infection intensities⁶¹. A direct role for IgE in host protection has been difficult to establish, and, instead of having a functional role, parasite-specific IgE levels in humans may represent a useful biomarker of a type 2 immune response. Animal models have revealed that B cells are important, although not essential, in resistance to *T. muris* infection^{73,86}. However, how B cells contribute to the protective immune response is unclear, and their contribution may not be related to their role in antibody production. Thus, B cells can also act as antigen-presenting cells⁸⁷ and cytokine-producing regulatory cells^{88,89} and, therefore, could influence the development of either type 1 or type 2 immune responses and worm expulsion.

In humans with chronic trichuriasis and in mice infected with low numbers of eggs, regulation of the gut

Fig. 4 | The anti-parasite effector mechanisms induced by the protective immune response. It is not known whether effector mechanisms similar to those observed in animal models also operate in humans, although it is a plausible hypothesis. **a** | In strains of mice resistant to *Trichuris muris* infection, the type 2 immunity cytokine IL-13 increases the rate of epithelial turnover, thereby displacing the parasite from its intracellular niche⁸⁴. Resistance to infection also correlates with an increase in goblet cell numbers⁸¹. Through the use of mucin-deficient mouse strains, mucin 2 and mucin 5, subtypes A and C^{80,81} have been shown to be important in resistance to *T. muris*, probably via direct interactions with the parasite in the gut. Changes to gut physiology, including increased muscle contractility, are also thought to contribute to parasite expulsion. **b** | In mice resistant to *Ascaris* spp. infection, elimination of parasites from the gut involves the 'weep and sweep' mechanism (increased fluid secretion and muscle contractility)¹³⁵. The mechanisms of lung immunity are unclear but probably involve type 2 immunity-controlled effector mechanisms. Both neutrophils and eosinophils infiltrate the lungs. Even less understood is liver immunity, although reactive oxygen species (ROS) have been implicated in the mechanism of resistance. T_H2 cell, type 2 T helper cell.

pathology induced by a large burrowing parasitic nematode is crucial in the maintenance of gut barrier function and prevention of sepsis. Regulation of pathology has been examined in some detail in the mouse model, and considerable evidence supports IL-10 as the regulatory cytokine vital in regulating IFN γ -mediated intestinal pathology and host protection^{90,91}. Interestingly, in human trichuriasis, the quantitative trait locus on chromosome 9, mentioned above, contains genes that can influence IL-10 levels³⁰. The cellular source of IL-10 is still debated, with FOXP3⁺ T_{reg} cells and other CD4⁺ T cell populations as probable contributors⁶⁸.

Insights from animal models — *Trichuris* spp. and their relationship with the microbiota. The close relationship between whipworms and the microbiota in the intestinal niche extends beyond the trigger for egg hatching⁵⁴. The presence of *Trichuris* spp. infection alters both the numbers and the composition of the microbiota, and this alteration has been reported for *T. muris* in mice^{92,93} and *T. suis* in pigs^{94,95} and in some, but not all, human studies^{96,97}. Studies of *T. muris* in mice have revealed that for fitness the parasite has to acquire its own distinct microbiota from the host. The microbiota of *T. muris* is dominated by the Bacteroidetes and Firmicutes phyla, with a statistically significant rise in the proportion of bacteria of the Proteobacteria phylum that is not observed in the infected host microbiota⁹⁸. Further, successful infections require the presence of host microbiota, and, remarkably, the *T. muris*-induced changes in the host microbiota may

limit the success of subsequent infections⁹⁸. In case of subsequent infections, parasite numbers are lower than the numbers from first-time infections, thereby providing a mechanism to limit host pathology and support chronicity of infection.

***Ascaris* spp.**

Ascaris spp. eggs are very robust owing to their outer corticated coat (a layer of mammillated (with round protuberances) albuminous material) and can survive in the environment for long periods of time (estimates include up to 6 years in Germany and 14 years in Russia), although the majority of eggs probably die on shedding⁹⁹. Evidence exists that tropical soils may be depleted of *Ascaris* spp. eggs and those of other STHs, including *Trichuris* spp., within 2 months, if no further contamination occurs¹⁰⁰.

The life cycle of *Ascaris* spp. and the timing of each step have proved difficult to precisely define (FIG. 3). An early and extensive study in pigs¹⁰¹ described how, after hatching, larvae are released in the small intestine while still in the sheath of the first moult, and such L2 larvae migrate to the caecum and proximal colon, where they penetrate the mucosa. However, a more-recent study¹⁰² found that both the first and second ecdysis (moult) occur in the egg, before eggs hatch in the large intestine, and such retention of two moult sheaths is thought to be a feature favourable to parasite development. The L3 larvae then undergo a hepato-tracheal migration, a phenomenon that distinguishes the life cycle of *Ascaris* spp.

from that of *Trichuris* spp. L3 larvae migrate via the portal blood vessels to the liver, where the L2 cuticle is shed and some larval growth occurs. Subsequently, L3 larvae leave the liver and advance to the lungs via the bloodstream, reaching first the heart and then the pulmonary vasculature⁹⁹. In the lungs, the larvae penetrate the alveolar spaces and then migrate up the airway tree to the pharynx, where they are coughed up and swallowed. On their return to the small intestine, L3 moult to the fourth larval stage (L4 larvae) then undergo a final moult (L5) and develop to adult and sexually mature male and female worms¹⁰³. Male and female adult worms measure 15–25 cm and 20–35 cm, respectively, and their life expectancy has been estimated at 1–2 years¹⁰⁴. Adult worms produce unembryonated eggs that are shed in the faeces, where they develop to infectivity under appropriate conditions of temperature and moisture. The speed of the embryonation varies considerably according to the environmental conditions. For example, at 30 °C embryonation takes ~10–14 days, whereas at 17 °C it can take 45–55 days¹⁰⁵. As it is the case with *Trichuris* spp. eggs, *Ascaris* spp. eggs that fail to embryonate are non-infective.

The reason why the life cycle of *Ascaris* spp. includes a difficult and risky hepato-tracheal migration is unclear, although some authors have argued that this migration confers fitness benefits to the parasite including increased size of adult worms¹⁰⁶. What is clear is that larval migration contributes to both liver and lung pathology^{107,108}. Furthermore, the role of the liver in resistance to ascariasis is important but remarkably under-studied.

Human ascariasis — pathophysiology and immunology. Ascariasis is an excellent example of an infection that contributes to chronic morbidity; it particularly affects child growth via anorexia, malabsorption of nutrients and jejunal mucosal abnormalities, and it also has effects on cognitive development. The mechanisms underlying cognitive defects are not well understood but are probably nutritionally mediated, although the effect of systemic low-grade inflammation should not be disregarded. Owing to its large size, *A. lumbricoides* can also cause acute manifestations, including intestinal and biliary tract obstruction with related complications.

The relationship between humoral immune responses and *A. lumbricoides* infection in humans has been explored in various contexts^{109,110}. Several studies have established a clear negative association between parasite-specific IgE levels and infection intensity. For example, a study of Nigerian children showed evidence of a statistically significant relationship between raised levels of parasite-specific IgE against the *A. lumbricoides* protein antigen ABA-1 and putative immunity in children¹¹¹. Children with high IgE titres were less predisposed to heavy infection intensity than children with low titres, consistent with the association between elevated levels of parasite-specific IgE and reduced worm burdens observed in adults with trichuriasis. Furthermore, increased levels of inflammatory markers, such as C-reactive protein, were also detected in the putatively immune children compared with the infected children¹¹¹. By contrast, another study found

no relationship between humoral immune responses and current or future worm burdens¹¹². The reason for these conflicting results is not clear. *A. lumbricoides* infection was also associated with a highly polarized T_H2 cell-mediated response, with IL-4 and IL-5 responses predominating¹¹³. Two studies in Cameroonian children and adults provided further evidence of the role of cytokines produced by T_H2 cells during ascariasis, including IL-5, IL-9, IL-10 and IL-13 (REFS^{63,114}). In contrast to the earlier of the two studies⁶³, in the later study, the effects of cytokine production were more pronounced in children¹¹⁴. This finding led the authors to suggest that heterogeneity in cytokine responses may differ depending upon geographical location, owing to differences in transmission patterns or even historical differences in parasite dynamics. The authors concluded that these age-related and location-related differences may have implications for the differential effect of deworming programmes on immune responses. Finally, a study showed increased cytokine production by T_H2 cells in children who had been repeatedly treated for *A. lumbricoides* infection, providing evidence that long-term treatment may increase T_H2 cell-mediated anti-parasite immunity¹¹⁵.

Insights from animal models — the mouse model.

Our understanding of the immunology of ascariasis is much more modest than that of the immunology of trichuriasis. One reason is the fact that there is no rodent model of ascariasis that demonstrates the entire life cycle of *Ascaris* spp.¹¹⁶. However, mouse models do provide insights into the factors that influence early stages of infection and larval migration¹¹⁶.

The mouse model enables an assessment of pathophysiological alterations under different parasitic burdens^{117,118}, genetic backgrounds^{118–121}, host ages¹²² and egg infectivities¹²², and under repeated parasite exposure⁴⁴. The acute, early stages of infection are well established^{116,122} and demonstrate the physiological changes elicited by larval migration in the host, especially in the liver and lung. During larval migration in the liver, an intense inflammatory response is observed, particularly in resistant strains of mice¹²⁰ (FIG. 4). Of note, proteomic analysis of hepatic tissues from resistant (CBA/Ca) and susceptible (C57BL/6J) mice strains infected with *A. suum* demonstrated intrinsic differences between the two strains, suggesting that resistance might be associated with the oxidative phosphorylation pathway and reactive oxygen species production¹²¹ and differential expression of components of the complement system¹¹⁸.

In primary infections with *Ascaris* spp., larval migration to the lungs promotes a local type 2 inflammatory response, marked by early production of IL-5 followed by increased levels of IL-4, IL-5, IL-6, IL-33, CCL11 (also known as eotaxin), CCL2 (also known as MCP1) and CXCL10 (also known as IP10) and eosinophilia (excessive numbers of eosinophils in the blood)^{122–124}. Interestingly, this elevated type 2 immune response was associated with a marked increase in IL-13 production by type 2 innate lymphoid cells and other type 2 immune cells, and it provided protection against the rodent hookworm *Nippostrongylus brasiliensis*¹²⁵.

This robust type 2 inflammatory response is associated with lung pathology, characterized by persistent airway hyper-responsiveness resembling an extreme form of allergic airway disease¹²³. The severe impairment in respiratory function is aggravated by multiple exposures to the parasite despite the statistically significant reduction of parasitic burden⁴⁴, which results in a reduction in larval migration to the liver and lungs. The inflammatory influx of cells in both the lung parenchyma and the bronchoalveolar fluid is initially dominated by neutrophils and correlates with IL-6 production in lung tissue^{44,122,124}. As the infection progresses, mononuclear cells accumulate at the inflammatory site in response to larval migration, produce TNF^{44,122} and ultimately differentiate into M2 macrophages in the type 2 immunity environment¹²⁴. Interestingly, parasite antigens can modulate macrophage differentiation, dendritic cell maturation^{126–128} (with further evidence of the ability of the parasite to modulate the immune response observed in experimental models of lipopolysaccharide-induced inflammation¹²⁹ and autoimmune hepatitis¹³⁰) and the immune response to heterologous (that is, other than from the parasite) antigens¹³¹ and viral co-infection¹³².

The protective inflammatory response observed in the mouse model of ascariasis may not be parasite-specific, given that pre-sensitization with heterologous allergens (from house dust mite) protects from a subsequent *A. suum* infection¹²⁴. Conversely, pre-sensitization with *Ascaris* spp. antigens accelerates the mite-specific IgE response upon mite antigen inhalation¹³³. These findings indicate the possible cross-reactivity between *Ascaris* spp. and arthropod antigens.

Insights from animal models — the pig model. Another important animal model for ascariasis is the *A. suum* pig model. Pigs are costly to maintain, and inbred and knockout porcine strains are currently unavailable. Nevertheless, given the economic burden of *Ascaris* spp. infection on the food industry and the fact that pigs are natural hosts for *A. suum* infection, understanding the pathophysiology of ascariasis in the swine model, particularly in the gastrointestinal phase of infection, is highly relevant. Of note, the use of the pig model enabled an understanding of both parasite–host interactions during establishment of the infection and the mechanisms of intestinal worm expulsion^{134,135}. The initial phase of *A. suum* infection in pigs is very similar to the parasite migration observed in humans and induces both liver and lung pathology^{136–138}. As observed in *Ascaris* spp. infections in humans and mice, production of IL-5, IL-13 and eotaxin and an intense eosinophilia are observed^{135,139}. Blood basophilia (excessive numbers of basophils) and intestinal mastocytosis (accumulation of mast cells) are also common^{139–141} and may contribute to type 2 immunity induced by infection. Although the mechanisms by which *Ascaris* spp. parasites are expelled from the gut are less well defined than those of *Trichuris* spp., evidence suggests that elimination from the gut involves the ‘weep and sweep’ mechanism, an increase in fluid secretion and muscle contractility¹³⁵. Further, there is some evidence in pigs naturally exposed to *A. suum* infection that continual exposure to infective

larvae emerging from the eggs may inhibit larval migration from the intestine¹⁴². In the pig model, profound changes in the gut microbiota occur during *A. suum* infection, especially in the proximity of the initial site of egg hatching¹⁴³. Thus, *Ascaris* spp. infection leads to a remarkable reduction in the gut microbial diversity, a reduction that is not related to worm burden. Moreover, the infection affects the abundance of specific microbial genera, particularly in the proximal colon¹⁴³. The relevance of microbial composition alterations due to *Ascaris* spp. infection remains unknown. Finally, pathophysiological changes similar to those described in humans, mice and pigs have also been observed in other animal models including calves¹⁴⁴, guinea pigs¹⁴⁵, rabbits¹⁴⁶, gerbils¹⁴⁷ and non-human primates^{148–150}.

Diagnosis, screening and prevention

Clinical presentation

Trichuriasis. Clinical disease is caused largely by inflammation of the caecum and large intestine, due to the presence of adult worms inducing a local inflammatory response and blood loss (from bleeding and oozing at the mucosal entry sites of worms) as they forage across the mucosa (FIG. 5a). Blood loss in trichuriasis has been estimated to be 0.005 ml per worm per day¹⁵¹. Risk of anaemia is substantial among those with heavy infection intensities (defined as ≥ 800 worms¹⁵¹ or $>5,000$ eggs per gram of stool (EPG)¹⁵²) or those co-infected with hookworm^{153,154}. Clinical disease in individuals with *T. trichiura* infection is related to parasite burden. Most inhabitants (both children and adults) of endemic areas are infected with relatively few worms (that is, <15 adult worms¹⁵⁵), and such infection intensities are associated with mild symptoms. Eosinophilia, if present, tends to be mild. However, in these regions, individuals are at risk of infection by other enteric parasites and are exposed to a range of environmental hazards. Non-specific symptoms of urticaria (itchy skin rashes), anorexia, abdominal pain and other gastrointestinal symptoms are difficult to attribute to any single cause, although they have been associated with *T. trichiura* infection¹⁵⁶. By contrast, heavy infection intensities with several hundreds or even thousands of worms^{157,158} are often associated with colitis and substantial illness that may present as chronic iron deficiency anaemia in adults¹⁵⁷, whereas children may present with failure to thrive, diarrhoea, which may be bloody, and short stature for their age, with or without symptoms of colitis or a severe illness. Even mild trichuriasis may be accompanied by growth retardation in children¹⁸, whereas TDS may be associated with severe malnutrition and growth stunting^{18,159}. TDS, also known as massive infantile trichuriasis, is a severe illness associated with iron deficiency anaemia, chronic mucoid diarrhoea, rectal bleeding, rectal prolapse (a consequence of increased straining and/or peristalsis) and finger clubbing^{155,160}. The pathogenesis of clubbing, a non-specific manifestation of many chronic diseases, is unknown but may relate to increased platelet-derived growth factor in the nail beds¹⁶¹. The triad of finger clubbing, rectal prolapse and chronic diarrhoea in children used to be pathognomonic of trichuriasis in endemic areas: 3–5% of children of 6 months to 6 years of age

Fig. 5 | **Clinical complications of trichuriasis and ascariasis.** **a** | Colonoscopic image from a 15-year-old girl with *Trichuris* dysentery syndrome (TDS). The colonic mucosa is covered with parasites (seen are posterior ends tethered to the mucosa). Note petechial (black arrow) lesions and blotchy mucosal haemorrhages (white arrow). **b** | Abdominal plain radiograph demonstrating 'tramline' appearance caused by a heavy intestinal infestation by *Ascaris lumbricoides*. The duodenum is packed with worms, resulting in a whorled (spiral) appearance of black radiolucent worms outlined by gas. **c** | Small-bowel obstruction by *A. lumbricoides*. The image shows a mass of *A. lumbricoides* worms collected from a section of obstructed small intestine following enterotomy in a 3-year-old boy in South Africa. Part **a** is adapted with permission from REF.¹⁵⁷, Elsevier. Part **b** is adapted from REF.³¹¹, Springer Nature Limited. Part **c** is adapted from REF.³¹², CC BY 3.0 (<https://creativecommons.org/licenses/by/3.0/>).

were estimated to have recurrent rectal prolapse in a region of the Caribbean¹⁶². However, with improvements in environmental hygiene and access to anthelmintics, TDS and rectal prolapse are now infrequent. TDS has more recently been recognized as a problem in adults presenting with severe iron deficiency anaemia¹⁵⁷, and this observation probably reflects poor clinical recognition of trichuriasis in adults living in conditions of severe poverty and who are not included in anthelmintic treatment programmes. Heavy infection intensities may be associated with increased intestinal permeability and a chronic inflammatory response, as indicated by elevated circulating levels of the pro-inflammatory cytokine TNF¹⁶³.

T. trichiura may be a chance finding in individuals undergoing colonoscopy for abdominal pain and altered bowel habits^{164,165}. In individuals with heavy infection intensities, colonoscopy shows numerous motile worms tethered to the intestinal mucosa by their anterior ends^{157,165}. Histopathology of the large intestine in patients with trichuriasis often shows only mild changes, with increased numbers of inflammatory cells in the lamina propria, particularly in adults^{157,159}, whereas in children histological changes range from mild inflammation to localized cryptitis at worm attachment sites to a highly inflamed intestinal mucosa that is oedematous, eroded and friable^{64,158}. In individuals with heavy infection intensities, adult worms may be found from the caecum to the rectum, and the mucosa is studded with bleeding points representing previous mucosal entry points of foraging adult worms^{157,159}.

Prolonged mucosal bleeding and inflammation affect the nutritional status of children, particularly those on marginal diets (that is, low in iron and other essential nutrients)¹⁵². Further, the presence of adult worms may also affect nutrient absorption through mucosal damage or disruption of the intestinal microbiota, although evidence for an effect of disrupted microbiota is limited^{97,166}. Damaged mucosa may have increased

susceptibility to infections with other intestinal pathogens with which *T. trichiura* has been associated, such as *Entamoeba histolytica*¹⁶⁷. *T. trichiura* infection has been shown to correlate with the presence of both *A. lumbricoides* and *Campylobacter* spp.^{97,168}. Whether multiple intestinal infections are simply coincidental or whether they influence each other's pathogenicity in humans is unclear¹⁶⁹, although exacerbated disease and pathology have been reported in pigs co-infected with *T. suis* and *Campylobacter jejuni*¹⁷⁰.

Ascariasis. In endemic areas, the majority of *A. lumbricoides* infections cause mild or no symptoms. Clinical disease is restricted to a small percentage of individuals with a high parasite burden, as most individuals harbour only a few worms^{171,172}, although there are no up-to-date figures on the percentage of clinical cases. The clinical manifestations are directly related to the parasite life cycle and depend on the infection intensity. During larval migration through the airways (10–14 days after infection), classic respiratory alterations, including lung infiltration (visible on the chest radiograph), intense eosinophilia, cough and wheeze are observed and are known as Löffler syndromes¹⁷³. Urticaria, cough, dyspnoea, haemoptysis (coughing up blood) and abnormal breath sounds on auscultation are also non-pathognomonic signs associated with larval migration through pulmonary tissue. Adult parasites dwelling in the small intestine can induce, depending on their numbers, various gastrointestinal outcomes, including upper gastrointestinal bleeding, small-bowel obstruction (FIG. 5b,c), volvulus (twisting of an intestinal tract that results in obstruction and/or bowel ischaemia), intussusception (folding of the intestinal tract into the section of intestine that is immediately ahead), peritonitis, haemorrhagic infarction of the bowel and perforation^{174,175}. Adult worms may also migrate to extra-intestinal sites, and hepatobiliary and pancreatic ascariasis (HPA) may then occur, leading to biliary colic, acute cholecystitis, acute

pancreatitis, acute cholangitis (inflammation and/or infection of the biliary tree) and hepatic abscess¹⁷⁶. Intestinal perforation and peritonitis¹⁷⁷, often following appendicular ascariasis¹⁷⁸, is a rare but severe and often fatal surgical emergency caused by ascariasis in endemic areas. Heavy infection intensities with ascariasis are a common cause of surgical emergencies in endemic regions, and these emergencies are primarily caused by obstruction of the narrow intestinal lumen of a young child with a bolus of *A. lumbricoides* worms¹⁷⁹.

Asthenia (physical weakness), lack of appetite, abdominal pain and/or distension, nausea, diarrhoea and weight loss are common in children with severe intestinal ascariasis in endemic areas¹⁷⁶. Moderate to heavy infection intensities in children have been associated with impairment in physical and mental development¹⁸⁰ and may also contribute to malnutrition¹⁸¹ and deficiency of vitamins A and C¹⁸².

Diagnosis of trichuriasis and ascariasis

As with other STH infections, the laboratory diagnosis of ascariasis and trichuriasis relies on the examination of a stool sample to determine the presence and, whenever possible, the quantity of parasite eggs. Currently, the WHO recommends the use of the Kato–Katz method to examine stool samples for STH infections by direct microscopy¹⁸³ and to assess two slides per sample¹⁸⁴. Other parasitological methods include formol–ether concentration, McMaster, FLOTAC and Mini-FLOTAC, and the sensitivity of all these methods varies according to the infection intensity¹⁸⁵ (TABLE 1). Direct observation of saline smears, although of low sensitivity, is the most widely used microscopic method to examine stools. New parasitological methods, such as mobile phone microscopy¹⁸⁶ and FECPAKG2 (a sedimentation method coupled with imaging and remote identification and quantification of STHs)¹⁸⁷ have been developed but require extensive evaluation.

Considering the reduced sensitivity of microscopy-based parasitological methods, molecular-based diagnostic assays have been developed, aiming to improve sensitivity and specificity. The reported sensitivities of molecular methods are superior to those of microscopy-based methods for the diagnosis of both ascariasis^{188–191} and trichuriasis^{190,191}, despite the lack of an adequate gold standard for comparison¹⁹². Of note, most molecular-based assays have been developed as multiplexed^{193–195} or multi-parallel assays^{189,196,197} for detection of different parasites. However, the development of these methods is hampered by the requirement for specific, more-expensive equipment and the lengthy procedure of DNA extraction from the stool samples, both of which may limit the application of molecular diagnostic assays in field settings. A colorimetric isothermal assay, consisting of a one-step DNA amplification method, has also been developed for the diagnosis of ascariasis and trichuriasis, combining high sensitivity and high tolerance to substances present in faecal samples that might interfere with the assay¹⁹⁸ (such as complex polysaccharides, salts, lipids and urate, among others¹⁹⁹), and might be a promising tool for diagnosis in the field. Nevertheless, at present, molecular-based

assays remain restricted to research groups working in specialized laboratories, and none of them has been rolled out for routine use in endemic regions. Thus, for the moment, microscopy-based analysis remains the mainstay for the diagnosis of ascariasis and trichuriasis — there is still considerable demand for such diagnostics from physicians in local hospitals and clinics and the mothers of children living in communities in endemic areas, who often attribute a large amount of illness in their children to the presence of these parasites.

Advantages and limitations of diagnostic methods.

Microscopy-based and molecular-based diagnostic methods are only effective after infections have become patent. Microscopy-based methods have very limited sensitivity for infections of light intensity¹⁸⁵, with the intensity of *T. trichiura* and *A. lumbricoides* infections estimated and classified as light (1–4,999 EPG and 1–1,000 EPG, respectively), moderate (5,000–49,999 EPG and 1,001–9,999 EPG, respectively) or heavy ($\geq 50,000$ EPG and $\geq 10,000$ EPG, respectively), according to the WHO classification²⁰⁰. By contrast, molecular-based assays, although more-expensive and of limited field applicability, enable detection of infections of low intensity in areas where anthelmintic control programmes have reduced prevalence and infection intensity to very low levels and where local or regional elimination strategies are being considered. The use of more-sensitive assays, such as quantitative PCR, at central laboratories might be justified under such circumstances, despite the need for sophisticated and costly equipment and trained personnel. Low-cost, field-applicable assays (such as lateral flow assays to detect specific parasite antigens in stool samples) are presently not available but would increase considerably the effectiveness of control programmes, by assisting in making decisions about the frequency of anthelmintic treatment and what population groups should receive treatment.

Prevention of trichuriasis and ascariasis

The prevention of trichuriasis and ascariasis, as well as any other STH infections, relies on the combination of several approaches that reduce prevalence. Among them, the WHO guidelines on preventive chemotherapy based on MDA in endemic areas aim to reduce the morbidity in preschool and school-age children by lowering the prevalence of infections of moderate and heavy intensity¹¹. Preventive chemotherapy is an important tool for reduction of prevalence and morbidity of both diseases, with a reduction of up to 80% in the overall parasite burden and prevalence in endemic areas^{201–203}. In 2017, a WHO Guideline Review Committee revisited the previous guidelines and provided updated global, evidence-informed recommendations on preventive chemotherapy⁸ in areas endemic for STHs; however, this approach represents a short-term strategy for control of helminth infections, as reinfection often occurs in endemic areas in the absence of clean water, sanitation and hygiene²⁰⁴. The water, sanitation and hygiene (WASH) programme advocates improvements in access to water (in terms of water quality and

Table 1 | Diagnostic methods for *Trichuris trichiura* and *Ascaris lumbricoides* infections

Test	Output	Sensitivity (%)		Specificity (%)		Advantages	Limitations
		<i>T. trichiura</i>	<i>A. lumbricoides</i>	<i>T. trichiura</i>	<i>A. lumbricoides</i>		
Direct microscopy ^{185,303}	Egg detection	62.8	52.1	97.5	99.6	Low cost	Positive results only at high parasitic burden
Kato–Katz ^{185,303–305}	Egg detection and egg quantification	62.8–91.0	56.9–88.1	97.5	99.6	Relatively low cost; possible to determine the burden of infection	Overall low sensitivity (especially at light infection intensities); need for a qualified microscopist
Formol–ether ¹⁸⁵	Egg detection	81.2	56.9	97.5	99.6	Relatively low cost	Does not detect unembryonated eggs of <i>Ascaris</i> spp.
FLOTAC ³⁰⁵	Egg quantification	88.7–100	79.7–100	97.5	99.6	Detection of different STHs simultaneously	Requires centrifugation steps with two different rotors; relatively high cost
Mini-FLOTAC ³⁰⁶	Egg quantification	76.2–91.5	63.3–75.5	97.5	99.6	Detection of different STHs simultaneously	Limited sensitivity (sensitivity comparable to that of the Kato–Katz method but lower than that of FLOTAC)
FECPAK ³⁰⁶	Egg quantification	59.8–65.8	58.9–75.6	97.5	99.6	Detection of different STHs simultaneously; simple procedure with results within an hour	Requires internet connection
McMaster ^{303,307}	Egg quantification	61.1–81.8	75.6–80.3	97.5	99.6	Relative low cost; enables quick counting of eggs; may be applicable for monitoring large-scale treatment programmes	Need for a special counting chamber
LAMP assay ^{192,198,308}	Identification of DNA from <i>Ascaris</i> spp. or <i>Trichuris</i> spp.	100	96.3–100	100	100	Possible to detect multiple infections by multiplexed assays; high specificity	Risk of low sensitivity due to the presence of inhibitors in the faecal sample; decreased sensitivity if formalin is used for fixation of samples; requires specialized equipment and has restricted use in the field
qPCR ³⁰⁶	Quantification of DNA from <i>Ascaris</i> spp. or <i>Trichuris</i> spp.	72.3–100	85–100	100	100		

A. lumbricoides, *Ascaris lumbricoides*; LAMP, loop-mediated isothermal amplification; qPCR, quantitative PCR; STHs, soil-transmitted helminths; *T. trichiura*, *Trichuris trichiura*.

quantity and distance to water) and sanitation (in terms of access to latrines, their proper maintenance and faecal waste management), the use of hygiene practices and changes in behaviour related to environmental and personal hygiene^{205,206}. Reduced odds of *A. lumbricoides* and *T. trichiura* infections are associated with treated water, access to sanitation and hygiene procedures (such as hand washing before eating and after defaecation and the use of soap)²⁰⁷. However, there is an urgent need to gather stronger evidence to support the role of WASH programmes in the control of STH infections²⁰⁸.

Preventive chemotherapy. In contrast to most regimens for individual patient management, preventive chemotherapy programmes, advocated since 2001 by the WHO, rely on single-dose treatment (TABLE 2). Preventive chemotherapy involves periodic administration of

recommended anthelmintics, usually a single dose of oral albendazole or mebendazole to preschool and school-age children, women of reproductive age (as well as pregnant women in the second and third trimesters and lactating mothers) and adult groups with high risk of exposure to STH infections (for example, tea pickers). The recommended treatment schedule (once or twice per year) is determined by the initial prevalence of STHs^{11,209}. The goal of preventive chemotherapy programmes was to achieve a minimum coverage of 75% of the most affected groups by 2020. In 2017, >598 million children were treated in endemic regions, corresponding to 69% of all children at risk²⁰⁸, indicating that the 2020 targets are nearly met. Thus, the WHO set new targets and indicators²¹⁰: to achieve and maintain elimination of STH morbidity (defined as the prevalence of moderate and heavy infection intensities below 2%) in

preschool and school-age children by 2030; to reduce the number of drug tablets needed in preventive chemotherapy for STH infections; to increase domestic financial support for preventive chemotherapy for STH infections; to establish an efficient STH infections control programme in adolescent, pregnant and lactating women; to establish an efficient strongyloidiasis (an STH infection caused by *Strongyloides* spp. nematodes) control programme in school-age children; and to ensure universal access to at least basic sanitation and hygiene by 2030 in STH-endemic areas.

Epidemiological surveillance. The high-throughput performance of serological assays indicates the suitability of these tools in epidemiological surveillance. The development of serological tools to improve the detection of prepatent infections could improve the effectiveness of surveillance during elimination programmes. However, the development of such assays is largely hampered by the lack of antigen specificity — owing to cross-reactivity between helminth antigens^{211–214}, and even between helminth and arthropod (such as mosquito and tick) antigens^{215,216} — and the inability to discriminate between past and current infections. Although serological assays are available for the diagnosis of animal infections^{217–220}, serological assays of human infections are restricted to detection of *A. suum*²²¹ in humans. Of note, anti-*A. suum* IgY formed immune complexes with *A. lumbricoides* antigens in serum from patients with ascariasis, with diagnostic sensitivity and specificity values of 80% and 90%, respectively²²², and, therefore, showed potential for immune-based diagnosis of ascariasis. Although on the one hand antigen cross-reactivity reduces the ability to discriminate among helminth infections, on the other hand serological assays using cross-reactive or conserved epitopes among different helminths would be useful for the control of STH infections, particularly in the application and assessment of parasite control achieved using MDA (see Outlook).

Vaccines. Vaccines might reduce the parasite burden and, consequently, the morbidity and transmission of infection (see Outlook). Evidence from experimental murine models indicated that continuous exposure to *A. suum* eggs (three successive infections with 2,500 eggs

each) led to up to 98% protection, measured as larval reduction in the host tissues^{44,223}. In mice, immunization with extract of adult *T. muris* worms or excreted–secreted proteins induced a high degree of protection (up to 100% larval reduction)^{224,225}. The development of vaccines using defined antigens against *A. lumbricoides* and *T. trichiura* has been pursued, but it is still restricted to experimental models, and no vaccines against *A. lumbricoides* or *T. trichiura* are currently being assessed in clinical trials. The selection of new vaccine candidates and the understanding of protective mechanisms induced by immunization might open new perspectives for the control of these infections in endemic areas, as individual or combined ('pan-helminth') vaccines²²⁶.

Management

As well as their prevention, the control and treatment of ascariasis and trichuriasis, like other STH infections, can be achieved through various strategies that include environmental sanitation and hygiene, health education and the use of anthelmintic drugs. Environmental sanitation and hygiene are effective, but appreciable reductions in prevalence and infection intensity take time. Indeed, it is difficult to distinguish the effects of WASH initiatives from those of anthelmintic drugs in control programmes²⁰⁸. Improved methods to assess levels of environmental exposure to STHs and of uptake and usage of WASH directives will contribute to understanding the role of WASH programmes as adjuncts to deworming programmes. By contrast, the use of effective and safe anthelmintic drugs has been shown to be effective and rapid in reducing prevalence, intensity and morbidity of these infections. Treatment of ascariasis and trichuriasis includes management of diagnosed patients with the aim of cure and MDA of anthelmintic drugs to populations in endemic areas to reduce the burden of disease (preventive chemotherapy).

The current drugs recommended by the WHO for the treatment of STH infections are albendazole, mebendazole, levamisole and pyrantel pamoate^{11,227}. Albendazole and mebendazole are the two benzimidazoles that have been used most widely for decades against STHs in the treatment of individual patients and in MDA programmes. For MDA programmes, millions of tablets are donated each year.

Table 2 | Recommended preventive chemotherapy regimens and efficacy of anthelmintic drugs

Treatment	Mechanism of action	<i>T. trichiura</i> infection			<i>A. lumbricoides</i> infection		
		Preventive chemotherapy ^a	Cure rate (%) ^b	Egg reduction rate (%) ^b	Preventive chemotherapy ^a	Cure rate (%) ^b	Egg reduction rate (%) ^b
Albendazole	β-Tubulin binding	Once	32.1	64.3	Once	96.5	99.7
Mebendazole	β-Tubulin binding	Once	44.4	80.7	Once	96.8	99.5
Albendazole–ivermectin	NA	Once	60.0	95.5	Once	96.7	99.9
Levamisole	L-subtype nAChR agonist	Once	23.4	41.8	Once	93.0	97.0
Pyrantel pamoate	L-subtype nAChR agonist	Once	28.5	62.3	Once	97.5	91.7

A. lumbricoides, *Ascaris lumbricoides*; NA not applicable; nAChR, nicotinic acetylcholine receptor; *T. trichiura*, *Trichuris trichiura*. ^aBased on REF.²²⁷. ^bAfter single dose administration, based on REF.²³¹.

Treatment of trichuriasis

Although the recommended monotherapies are effective when used at single oral doses for preventive chemotherapy, none of them shows acceptable efficacy (egg reduction rates >90% based on the target product profile, which describes the desired drug characteristics, for drugs used for STHs)²²⁸ against *T. trichiura* infections at single doses (TABLE 2). However, the efficacy increases when the drugs are used in the recommended dosing schedules. A double-blind clinical study on Pemba Island, Tanzania, showed that mebendazole treatment (twice a day for 3 days) achieved considerably higher cure and egg reduction rates against *T. trichiura* infections than single-dose treatment (cure rate 42.9% versus 6.8% and egg reduction rate 98.1% versus 71.7%) in school-age children²²⁹. Why anthelmintic drugs are less effective against *T. trichiura* infections than against other STH infections is not known, but the location of the parasite (as discussed in the Outlook section) might have a role.

Treatments under investigation. Owing to this low efficacy of standard monotherapy, monodose combination chemotherapy has been widely advocated, which includes the advantages of a single administration and drug combination therapy. Since 2017, albendazole–ivermectin is on the WHO essential medicine list for the treatment of STH infections including strongyloidiasis²³⁰. This drug combination was classified as high priority combination²³¹, as this treatment is already widely used for lymphatic filariasis (an infection caused by the bite of a mosquito carrying nematodes of the Filarioidea family). Despite the large scale use of this drug combination, the available efficacy data for STH infections are limited²³², and a multi-country randomized controlled double-blind trial has been launched to provide more robust evidence on the efficacy and safety of co-administration of ivermectin and albendazole²³³.

As moxidectin has been approved for the treatment of onchocerciasis (also known as river blindness, an infection caused by the bite of blackflies carrying the nematode *Onchocerca volvulus*) by the FDA²³⁴, albendazole–moxidectin might serve as an alternative drug combination to albendazole–ivermectin. Albendazole–moxidectin, used at the recommended dosages, was safe and effective against *T. trichiura* infections²³⁵. As for albendazole–ivermectin, large-scale trials to establish the effectiveness of albendazole–moxidectin are necessary²³⁵.

In contrast to the recommended treatments, ivermectin²³⁶ or moxidectin²³⁵, oxantel pamoate is more effective, having excellent trichuricidal properties²³⁷. To compensate for lack of efficacy of oxantel against *A. lumbricoides* and hookworm, oxantel has been combined with pyrantel pamoate (for example, Quantrel (Johnson & Johnson)). Several clinical trials have successfully demonstrated that a combination of albendazole and oxantel pamoate is safe and efficacious²³⁸. A network meta-analysis found that a single dose of this combination was associated with an estimated cure rate of 88.7% and an egg reduction rate of 96.7%²³¹. Efforts are ongoing to determine whether any existing data on oxantel pamoate (from veterinary medicine,

in which the drug is widely available, or from regions where it is registered for use in humans, for example, the Philippines) can be utilized to support registration of oxantel pamoate with the European Medicines Agency and/or the FDA, with the ultimate goal of using it as combination drug in treatment campaigns.

Emodepside, a veterinary anthelmintic licensed under the names Profender (Bayer) and Procox (Bayer), is the only drug in the late stages of clinical development, in the depleted drug development pipeline for STH infections. Emodepside is a cyclo-octadepsipeptide that targets the evolutionarily conserved calcium-activated potassium channel slowpoke 1 (SLO-1) and the latrophilin receptors LAT-1 and LAT-2 (REF.²³⁹), which are involved in nematode neuromuscular function. The drug is currently undergoing clinical testing against onchocerciasis. In laboratory models of STH infections, emodepside showed a broad spectrum of activity against the major STHs²⁴⁰. Thus, emodepside should also be considered for development as an anthelmintic drug, although it has the disadvantage of high production costs, as it is a semi-synthetic compound whose precursor is a metabolite of the fungus *Mycelia sterilia*. Testing of other SLO-1 inhibitors is currently ongoing.

Anthelmintic drug resistance. To date, there is no evidence of resistance to benzimidazoles in humans²⁴¹. However, the drug selection pressure that led to widespread anthelmintic drug resistance in veterinary helminths is now similar for human STHs, owing to the large-scale use of preventive chemotherapy. The reasons why it is difficult to assess the presence of anthelmintic drug resistance in humans include the variable drug efficacy, the lack of validated phenotypic or genotypic tests to detect resistance and working with difficult sample matrices (that is, stool). Efforts are ongoing to develop molecular and genomic screening tests of human STHs to identify mutations that are likely to be associated with benzimidazole resistance, on the basis of our understanding of resistance in veterinary helminths. Several initiatives are ongoing, including the STOP, DeWorm3 and Starworms (stop anthelmintic resistant worms) projects, that focus on the assessment of drug efficacy and the development of molecular methods for the detection of anthelmintic drug resistance²³⁰. It is important to monitor the presence of resistance-associated single-nucleotide polymorphisms in human STHs before resistance becomes clinically established.

Treatment of ascariasis

Several anthelmintics have been developed to effectively manage ascariasis, although their long-term effectiveness remains a concern. Albendazole, mebendazole, levamisole and pyrantel pamoate have high efficacy against *A. lumbricoides* in terms of both cure rates and egg reduction rates even with a single dose²⁴² (TABLE 2). Several other marketed anthelmintics, such as ivermectin (TABLE 2), moxidectin and tribendimidine, are also highly effective against *A. lumbricoides*²⁴².

Clinical disease resulting from ascariasis in children and adults includes intestinal obstruction (a common occurrence in children in endemic areas), peritoneal

ascariasis (due to the migration of *A. lumbricoides* larvae into the peritoneum through damaged intestine (such as an ulcer from typhoid fever, an inflamed appendix or, occasionally, an apparently healthy bowel)) and HPA, which commonly occurs in adults.

Conservative treatment is the mainstay in the management of patients with HPA and involves managing clinical signs and symptoms with appropriate treatment, such as bowel rest (that is, refraining from eating anything by mouth for a few days as required), intravenous fluids, analgesic antispasmodics and antibiotics followed by albendazole²⁴³. If adult worms are not expelled from the ductal lumen by 3 weeks after anthelmintic treatment, worms may be extracted by endoscopic retrograde cholangio-pancreatography (with endoscopic exploration of the bile and pancreatic ducts and extraction of worms), sphincterotomy (enlargement of the bile duct opening) or, occasionally, laparotomy²⁴⁴. Intestinal obstruction can often be managed conservatively, although those with signs of peritoneal inflammation generally require surgery to relieve the obstruction or to resect damaged bowel²⁴⁵.

Quality of life

Estimating the burden of STH infections

Cross-sectional and prospective observational studies from the 1990s or earlier indicated substantial adverse long-term effects of STH infections on several nutritional indices, such as stunting, and also on childhood cognitive development²⁴⁶. However, randomized controlled trials have been more equivocal in showing effects of STH infections on nutritional and cognitive indices, as these trials have shown conflicting results or results that did not reach statistical significance; more recent systematic reviews of intervention studies have been able to demonstrate only negligible effects on growth and nutritional parameters, cognition and mortality^{247–249}. A meta-analysis of observational and randomized treatment studies showed no overall effect on cognitive parameters in children in treatment trials but infection-related deficits in some parameters in observational studies, although these deficits were considered to be highly vulnerable to bias because of the poor methodological quality of many studies²⁵⁰. A systematic review of the benefits of nutritional supplementation (for example, iron) in addition to anthelmintic treatment highlighted that the evidence base was so weak that no nutritional supplementation could be recommended²⁵¹. Criticisms of these systematic reviews have focused largely on the following considerations: that including uninfected children or children with low parasite burdens in the analyses might have ‘diluted’ the effects of STH infections on the parameters measured; that the study populations may have been infected with a variety of different helminth species and, therefore, it would have been impossible to attribute species-specific effects; and that school absenteeism by the most affected children could have biased the results towards no effect, as these children would not have been examined as they did not attend school. A critical appraisal of systematic reviews noted the need for new studies designed and powered to overcome these limitations to enable morbidity from STH

infections to be measured more accurately²⁴⁶. Certainly, observational studies in children with heavy infection intensities have shown remarkable effects of treatment on ‘catch-up’ growth (compensatory accelerated growth after a period of slow development) after treatment, particularly in those with severe trichuriasis^{157,252,253}, but the frequencies of children at risk of severe disease have declined markedly in line with worldwide reductions in poverty rates^{254,255}.

Trichuriasis

In keeping with the challenges in quantifying the effects of living with STH infections outlined above, estimating the effects of trichuriasis on quality of life in populations in endemic areas is complicated by uncertainty in the estimates of prevalence and parasite burdens and imprecision in those effects on quality of life indices. Quality of life is most likely to be affected during chronic infections and/or infections of heavy intensity. Death is thought to be an unusual outcome, although no reliable estimates of mortality exist²⁵⁶. Nevertheless, trichuriasis probably has direct effects on several quality of life domains, such as economic productivity, educational performance and health, although there are limited data measuring such effects. Trichuriasis can affect cognition²⁵⁷, school performance²⁵⁸ and school absenteeism rates²⁵⁹ and, therefore, probably has direct effects on educational achievement and economic potential of individuals. Curative chemotherapy and treatment with iron in children with TDS can have dramatic effects on linear growth velocities¹⁵⁵. The benefits of deworming programmes in children has generated considerable controversy given negative findings of meta-analyses²⁴⁸, as discussed above. However, *T. trichiura* infection may impair developmental and cognitive abilities in children, although the benefits of treatment in reversing such deficits is hotly debated^{158,248,250,260}.

Health effects such as those associated with anaemia and poor growth will probably affect physical fitness²⁶¹ and economic productivity²⁶², as well as the quality of social interactions and well-being. Anaemia can be severe in vulnerable groups (such as pregnant women, whose iron reserves may be severely depleted), although it is usually not as pronounced as in those with hookworm infection^{154,157}. The various health consequences of infection can be summarized crudely in disability-adjusted life years (DALYs), an estimate of the number of years of ‘healthy life’ that are lost and are attributable to a specific infection, on the basis of morbidity and mortality data. For trichuriasis, estimated DALYs are highly variable between studies but were estimated at 0.213 million in 2017 (REF.²⁶³), with the greatest burden in the populous regions of Asia (~60% of DALYs). This figure represents a decline of 23% since 2007, largely due to reductions in poverty and improved access to anthelmintic drugs among high-risk groups. These estimates were calculated using disability weights (factors that quantify the magnitude of health loss associated with specific health outcomes) based on symptomatic infection, wasting and mild abdominopelvic problems, with no attributed mortality. Recently, girls and women of reproductive age have been included

as a high-risk group for anthelmintic treatment programmes, on the basis in part of the epidemiological links between *T. trichiura* infection and risk of anaemia in this group²⁶⁴. Trichuriasis is most common among those living in tropical regions in conditions of extreme poverty (that is, on less than US\$1.90 per day). Many of the factors that feed extreme poverty are linked to the risk of *T. trichiura* infection, which in turn contributes to the underlying causes of poverty. Thus, effective control of *T. trichiura* infection should contribute to reductions in poverty through improvements in health, educational achievement and economic productivity.

Ascariasis

As for trichuriasis, the burden of ascariasis is associated with the chronic and insidious effects that this disease has on the health and quality of life of infected individuals. *A. lumbricoides*, like *T. trichiura*, has a substantial role in childhood protein energy malnutrition and reduced food intake, leading to growth retardation, poor cognitive development, school absenteeism and poor academic performance. Collectively, these effects reduce an individual's productivity, thereby limiting the economic prospects of regions where *A. lumbricoides* is endemic^{265–267}.

The unique hepatic migration of *Ascaris* spp. can contribute to liver inflammation. An extensive prospective study in hospital patients in India revealed that in 14.5% of patients with liver abscess the cause was biliary ascariasis, and 11 patients had intact *Ascaris* spp. larvae within the liver abscess¹⁰⁷. High burdens of adult worms are associated with life-threatening complications in children and adults, generally caused by intestinal and biliary obstruction²⁶⁸ among those with worm burdens of >60 parasites²⁶⁹. Airway obstruction, a potential life-threatening event arising from *A. lumbricoides* infection, has also been reported^{270–272}; however, this condition is rare, and there are no available data on its prevalence. The global DALY estimate for ascariasis was 0.861 million in 2017 (REF.²⁶³). Compared with data published in 2007, ascariasis was associated with the largest decrease in DALYs among all intestinal nematode infections, possibly owing to deworming programmes and socio-economic development. Ascariasis has been associated with more-severe asthma symptoms among children living in urban areas of the tropics, an effect attributed to strong pro-allergic effects of low levels of exposure to the parasite^{273,274}.

Outlook

Drug treatment and parasitological monitoring

Complex and multifaceted challenges remain in the elimination of *Ascaris* spp. and *Trichuris* spp. infections. These challenges include the sustainability of preventive chemotherapy; the choice of at-risk groups (for example, at present, adult men are excluded from MDA programmes, and a study in Myanmar identified that this group has substantial burdens of both hookworm and *T. trichiura* infections²⁷⁵); the possible emergence of anthelmintic drug resistance; and the fact that a pan-STH vaccine²²⁶ is an ambitious endeavour. Furthermore, the emerging data on the effect of WASH

programmes²⁰⁸ suggest that while the prevalence of STH infection remains high, MDA will still be required, and the benefits of WASH programmes will only be realized in the longer term. Certainly, the funding of initiatives such as the DeWorm3 project²⁷⁶ is a welcome endeavour that will test the feasibility of interrupting transmission of STH infections using biannual MDA targeting all age groups, coupled with large-scale application of PCR assays for monitoring the efficacy of drug treatment. An argument that is gaining momentum is the need to move away from focusing on the treatment of only school-age children to a community-wide approach, especially in high transmission areas²⁷⁷. A large-scale randomized trial in Kenya that compared three treatment strategies (the annual treatment of the whole community, the biannual treatment of the whole community and the current focus of annually treating only children of 2–14 years of age) concluded that annual or biannual community treatment was more effective in reducing the prevalence and intensity of hookworm infections than treatment of school-age children only, but this approach needs to be explored in the context of infections with *Ascaris* spp. and *T. trichiura*²⁷⁸.

We urgently require well-designed, long-term epidemiological studies providing quantitative data, including data for appropriate mathematical modelling, to plan future elimination strategies. In this context, parasitological monitoring²⁷⁹, combined with the development of appropriate mathematical modelling approaches, is a key component required to improve our understanding of the efficacy of control strategies. New methods need to be developed to enable rapid measurement of the prevalence of STH infections in preschool children, school-age children, women of reproductive age and other at-risk groups, providing a more complete picture of the burden of STH infections in the entire community. In this context, the most urgent need is for accurate estimates of key parameters that can be fitted to mathematical models to assess the effect of treatment in key at-risk groups; such parameters include density dependence in worm fecundity (which is observed as a reduction in egg production with increasing worm burdens), parasite life expectancy, egg survival in the environment and age-specific force of infection, which describes the per capita rate at which susceptible individuals acquire infection²⁸⁰.

The development of new drugs

The long-term effectiveness of the drugs currently available to treat *Ascaris* spp. and *Trichuris* spp. infections is a major concern and underpins the need for novel drug discovery. Encouragingly, drugs with new mechanisms of action and new drug candidates from natural products are being discovered. Further, access to the genomes of these^{82,281} and many other parasites²⁸² offers the prospect of enhanced target-based screening for new anthelmintics. A chemogenomics approach (which takes the most promising drug targets in parasite genomes and explores their potential) is underway. For *Trichuris* spp., 40 priority targets were associated with 720 drug-like compounds (181 of which reached phase III/IV clinical trials for other human therapeutic applications and, therefore, would

Fig. 6 | Outlook for the development of novel drugs for soil-transmitted helminth infections. Chemogenomics approaches will help to identify new candidate anthelmintic drugs targeting *Ascaris* spp. and *Trichuris* spp. Targets common to all soil-transmitted helminths (STHs) will be of particular interest. Advanced, automated phenotypic screening platforms of putative new drugs will emerge. An improved understanding of the worm life cycle, host–parasite interactions and host immunity to infection, informed by imaging techniques, may assist in adding context to omics-based discoveries, and, as a result, additional candidate targets might be identified, as well as challenges in developing new therapies. The live imaging photo shows the front end of an adult *Trichuris muris* worm. The scanning electron microscopy image shows the front end of an adult *T. muris* worm, highlighting structures called cuticular inflations³¹³. The immunohistochemistry image shows neutrophils (red) in the lamina propria of the colon around an adult *T. muris* worm (arrows). The X-ray micro-CT images show 3D rendering of the host intestinal mucosa (pink). The positioning of adult *T. muris* within the epithelial cell layer (black arrows) is made clear by altering transparency of the rendering. Images courtesy of J. O'Sullivan and H. Smith, University of Manchester, Manchester, UK.

probably have good host tolerance²⁸³). For *Ascaris* spp., new targets with their variety of inhibitors may also offer new routes to drug discovery²⁸¹.

Phenotypic screening, using live, ex vivo nematodes, has resulted in the discovery of most currently available anthelmintics²⁸³ and is likely to remain an important approach in the future. New platforms encompassing automated phenotyping that are suited to high-throughput chemical screening for motility and growth impairment in *C. elegans* and parasitic nematodes are available²⁸⁴. Such platforms facilitate the testing of putative drugs across different parasite species, with the goal of discovering moieties with activity against trematodes and nematodes. The wealth of behavioural data on mutants of *C. elegans* is also an accessible resource in the search for new candidate drug targets²⁸⁵. Compounds active against parasites and *C. elegans* will facilitate genetic approaches to target identification. By this means, new classes of compounds with anthelmintic properties are emerging²⁸⁶, including some with activity against both adult and egg stages, which may interrupt transmission²⁸⁷. This feature could be important, as both *Trichuris* spp. and *Ascaris* spp. eggs can remain viable in soil for extended periods²⁸⁸.

The use of advanced imaging technologies may improve our understanding of parasite–host biology and facilitate the development of novel drugs against STHs in general (FIG. 6). One such example is X-ray CT, which provides re-constructed 3D images of parasites in situ and over time⁵². This technique can highlight in detail parasite interactions with host tissue. For example,

the attachment site of *T. trichiura*, the epithelial tunnel, remains poorly understood. To date the tunnel has only been viewed by scanning electron microscopy²⁸⁹ of the surface of the epithelial cells that line the gut lumen and by conventional histology, which provides a 2D view²⁹⁰. 3D imaging offers the potential to view the attachment site in a more-holistic way and has already begun to show the complexity of *T. muris* interactions with intestinal cells. This complex interplay may present particular challenges for worm clearance⁵². Further, acknowledging and addressing important differences in the biology of *Ascaris* spp. and *Trichuris* spp. will facilitate the development of bespoke strategies to reduce prevalence and control morbidity. Future investigations of mechanisms of resistance and pathophysiology in animal models must focus on more physiologically relevant dosing regimens (low-dose infection and repeated low-dose ('trickle') infections)²⁹¹. Mechanistic studies in mouse models must take into account the importance of context if we are to better model human trichuriasis and ascariasis. Such adjustments should include a consideration of the array of intrinsic and extrinsic host factors, such as genetics, age, sex, microbiota (which includes viruses, fungi and gut protozoa), co-infections, nutrition and reproductive state. Complex environmental factors affect individual variation in the immune status, and this interaction can be modelled, for example, in wild mouse populations²⁹² and semi-wild systems²⁹³.

Anthelmintic drug resistance mechanisms may involve pharmacokinetics, drug detoxification and target-site modifications, all of which can shorten the

useful lifespan of valuable compounds. Hence, discovering ways to circumvent resistance will be important in the future. Arguably the few compounds in repeated current use may increase the chances of resistance developing²⁹⁴. Increasing the pipeline of new compounds will be important, as well as rotating or combining drug treatments. Resistance may be under-reported if we only screen for known resistance-associated polymorphisms. Improved molecular markers²⁹⁵ are needed to better understand resistance, especially when planning large-scale deworming programmes worldwide.

Targeting liver immunity

Stimulating host immunity may offer a therapeutic avenue, and there is emerging evidence for the role of the liver in immunity to ascariasis^{116,296}. The liver proteome has been investigated in two inbred mouse strains, susceptible and resistant to *Ascaris* spp. infection¹¹⁹. Higher levels of mitochondrial proteins involved in oxidative phosphorylation were observed in the resistant strain (both at baseline and during infection) than in the susceptible strain. Thus, an intrinsic difference in the levels of reactive oxygen species in the liver could provide an advantage against the parasite in the resistant strain¹²¹. In another study, a lower burden of *Ascaris* spp. larvae was observed in the lungs of reinfected mice than in the lungs of mice infected for the first time. Further, lesions caused by hepatocyte necrosis and infiltration of eosinophils and neutrophils were more pronounced in the reinfected group; thus, the more pronounced hepatic immune response in the reinfected group resulted in a reduced lung larval burden⁴⁴. Novel therapies targeting the liver could conceivably stop larval migration, reducing tissue damage and impairing development of adult worms.

The development of vaccines

Concerns remain that MDA alone will not be sufficient to eliminate STH infections, owing to rapid reinfection in environments where long-lived eggs survive, poor drug efficacy particularly against *T. trichiura*, the possibility of drug resistance and a lack of access to clean water and adequate sanitation. Thus, vaccination will be a continued focus for the future. However, in contrast to the efforts made to develop an anti-hookworm vaccine, progress in anti-*Ascaris* spp. and anti-*Trichuris* spp. vaccines has been slow. Pigs exposed to a vaccine composed of UV-irradiated, and thereby attenuated, *A. suum* eggs demonstrated enhanced immunity to a challenge with infective eggs, evidenced by reduced numbers of migrating larvae and adult worms in the intestine²⁹⁷. However, exposure to a mixture of antigens carries the risk of inducing allergic responses due to the allergenic properties of these antigens. The genes encoding several chemically defined antigens have been cloned, the recombinant

proteins have been expressed, and six antigens have been targeted for further investigation²²⁶, including As14 (an antigen found in both larval and adult *Ascaris* spp. worms that induces a 64% reduction in the number of larvae after vaccination in mice²⁹⁸), As16 (REF.²⁹⁹) and As37 (REF.³⁰⁰). *T. muris* has not been studied as extensively as *A. suum* with respect to the development of recombinant antigens²²⁶. Antigens derived from the stichosome have induced substantial reductions in worm burdens in a mouse model²²⁵. Further, the *T. muris* whey acidic protein (rTm-WAP49), secreted from the parasite's stichosome and with tentatively ascribed pore-forming activity, has been proposed as a promising vaccine candidate³⁰¹, suggesting that the evaluation of *T. muris* recombinant proteins as immunogenic entities is gathering pace. rTm-WAP49 achieved a 48% reduction in worm burden in mice and showed high sequence conservation with the *T. trichiura* WAP proteins³⁰¹. More recently, a novel CD4⁺ T cell epitope-based vaccine has also been shown to promote protective immunity in the mouse model³⁰².

Final words

STHs are complex pathogens, and their control presents complex challenges, which differ according to context. Thus, formulating control guidelines and approaches that are universally applicable is a non-trivial task. A comprehensive approach including MDA, education and sanitation is crucial, in parallel with basic biological research. Enabling regions to take ownership of control programmes, thereby moving towards self-sustainability in both drug administration and drug procurement, is a key goal. In this context, new targets and indicators have been set by the WHO²¹⁰. For example, the number of regions supporting deworming programmes with domestic funds is scheduled to increase from 5 in 2023 to 25 in 2030. Further, improved sanitation is a major goal, with the ambitious target of decreasing open defaecation to 0% in STH-endemic areas by 2030, with progress towards this goal monitored from national surveys and census data. In addition to enabling regions to take ownership of control programmes, building a critical mass of scientists conducting infectious disease research in their home regions, where STH infections are endemic, is equally important. Multiple unmet needs exist in the field of basic biology of infection, including the need to develop affordable, sensitive diagnostic tools to monitor parasite prevalence and infection intensity and innovation in vaccine research. Nevertheless, the current pace of technological advances in biological research combined with the growth of multidisciplinary approaches suggests that living with STH infections will one day be the exception rather than the rule in regions where STHs are now endemic.

Published online: 28 May 2020

1. Araujo, A., Reinhard, K. J., Ferreira, L. F. & Gardner, S. L. Parasites as probes for prehistoric human migrations? *Trends Parasitol.* **24**, 112–115 (2008).
2. Hawash, M. B. et al. Whipworms in humans and pigs: origins and demography. *Parasit. Vectors* **9**, 37 (2016).
3. Ledger, M. et al. Parasite infection at the early farming community of Çatalhöyük. *Antiquity* **93**, 573–587 (2019).
4. Soe, M. J., Kapel, C. M. & Nejsum, P. *Ascaris* from humans and pigs appear to be reproductively isolated species. *PLoS Negl. Trop. Dis.* **10**, e0004855 (2016).
5. Mitchell, P. D. The origins of human parasites: exploring the evidence for endoparasitism throughout human evolution. *Int. J. Paleopathol.* **3**, 191–198 (2013).
6. Pullan, R. L., Smith, J. L., Jasrasaria, R. & Brooker, S. J. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. *Parasites Vectors* **7**, 37 (2014).
7. Hotez, P. J. et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. *PLoS Negl. Trop. Dis.* **8**, e2865 (2014).

8. World Health Organization. *Preventive chemotherapy to control soil-transmitted helminths in at-risk population groups: guideline* (WHO, 2017).
9. Hotez, P. J. Global deworming: moving past albendazole and mebendazole. *Lancet Infect. Dis.* **17**, 1101–1102 (2017).
10. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **388**, 1603–1658 (2016).
11. World Health Organization. *Eliminating soil-transmitted helminthiasis as a public health problem in children: progress report 2001–2010 and strategic plan 2011–2020* (WHO, 2012).
12. Yakob, L. et al. Slaving and release in co-infection control. *Parasites Vectors* **6**, 157 (2013).
13. Pullan, R. & Brooker, S. The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases? *Parasitology* **135**, 783–794 (2008).
14. Brooker, S., Clements, A. C. & Bundy, D. A. Global epidemiology, ecology and control of soil-transmitted helminth infections. *Adv. Parasitol.* **62**, 221–261 (2006).
15. Owada, K. et al. Spatial distribution and populations at risk of *A. lumbricoides* and *T. trichiura* co-infections and infection intensity classes: an ecological study. *Parasites Vectors* **11**, 535 (2018).
16. Global Health Data Exchange. GBD results tool. <http://ghdx.healthdata.org/gbd-results-tool> (2020).
17. Beer, R. J. The relationship between *Trichuris trichiura* (Linnaeus 1758) of man and *Trichuris suis* (Schrank 1788) of the pig. *Res. Vet. Sci.* **20**, 47–54 (1976).
18. Bundy, D. A. & Cooper, E. S. *Trichuris* and trichuriasis in humans. *Adv. Parasitol.* **28**, 107–173 (1989).
19. Summers, R. W., Elliott, D. E., Urban, J. F. Jr., Thompson, R. A. & Weinstock, J. V. *Trichuris suis* therapy for active ulcerative colitis: a randomized controlled trial. *Gastroenterology* **128**, 825–832 (2005).
20. Williams, A. R. et al. Immune responses and parasitological observations induced during probiotic treatment with medicinal *Trichuris suis* ova in a healthy volunteer. *Immunol. Lett.* **188**, 32–37 (2017).
21. Ghai, R. R. et al. Hidden population structure and cross-species transmission of whipworms (*Trichuris* sp.) in humans and non-human primates in Uganda. *PLoS Negl. Trop. Dis.* **8**, e3256 (2014).
22. Bundy, D. A., Cooper, E. S., Thompson, D. E., Didier, J. M. & Simmons, I. Epidemiology and population dynamics of *Ascaris lumbricoides* and *Trichuris trichiura* infection in the same community. *Trans. R. Soc. Tropical Med. Hyg.* **81**, 987–993 (1987).
23. Bundy, D. A., Cooper, E. S., Thompson, D. E., Anderson, R. M. & Didier, J. M. Age-related prevalence and intensity of *Trichuris trichiura* infection in a St. Lucian community. *Trans. R. Soc. Tropical Med. Hyg.* **81**, 85–94 (1987).
24. de Silva, N. R. et al. Soil-transmitted helminth infections: updating the global picture. *Trends Parasitol.* **19**, 547–551 (2003).
25. Schulz, J. D., Moser, W., Hurlimann, E. & Keiser, J. Preventive chemotherapy in the fight against soil-transmitted helminthiasis: achievements and limitations. *Trends Parasitol.* **34**, 590–602 (2018).
26. Elliott, D. E. in *Seisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management* (eds Friedman, L. S., Feldman, M., Brandt, L. J.) 2435–2457 (Elsevier, Philadelphia, 2006).
27. Wright, J. E., Werkman, M., Dunn, J. C. & Anderson, R. M. Current epidemiological evidence for predisposition to high or low intensity human helminth infection: a systematic review. *Parasites Vectors* **11**, 65 (2018).
28. Bundy, D. A. et al. Predisposition to *Trichuris trichiura* infection in humans. *Epidemiol. Infect.* **98**, 65–71 (1987).
29. Ellis, M. K. et al. Familial aggregation of human susceptibility to co- and multiple helminth infections in a population from the Poyang Lake region, China. *Int. J. Parasitol.* **37**, 1153–1161 (2007).
30. Williams-Blangero, S. et al. Two quantitative trait loci influence whipworm (*Trichuris trichiura*) infection in a Nepalese population. *J. Infect. Dis.* **197**, 1198–1203 (2008).
31. Costa, R. D. et al. Effect of polymorphisms on TGFB1 on allergic asthma and helminth infection in an African admixed population. *Ann. Allergy Asthma Immunol.* **118**, 483–488.e1 (2017).
32. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* **386**, 743–800 (2015).
33. Avery, R. H., Wall, L. A., Verhoeve, V. I., Gipson, K. S. & Malone, J. B. Molecular confirmation of *Ascaris suum*: further investigation into the zoonotic origin of infection in an 8-year-old boy with Loeffler syndrome. *Vector Borne Zoonotic Dis.* **18**, 638–640 (2018).
34. Sadaow, L. et al. Molecular identification of *Ascaris lumbricoides* and *Ascaris suum* recovered from humans and pigs in Thailand, Lao PDR, and Myanmar. *Parasitol. Res.* **117**, 2427–2436 (2018).
35. Monteiro, K. J. L. et al. Genetic diversity of *Ascaris* spp. infecting humans and pigs in distinct Brazilian regions, as revealed by mitochondrial DNA. *PLoS One* **14**, e0218867 (2019).
36. Betson, M., Nejsun, P., Bendall, R. P., Deb, R. M. & Stothard, J. R. Molecular epidemiology of ascariasis: a global perspective on the transmission dynamics of *Ascaris* in people and pigs. *J. Infect. Dis.* **210**, 932–941 (2014).
37. Nejsun, P., Betson, M., Bendall, R. P., Thamsborg, S. M. & Stothard, J. R. Assessing the zoonotic potential of *Ascaris suum* and *Trichuris suis*: looking to the future from an analysis of the past. *J. Helminthol.* **86**, 148–155 (2012).
38. Benjamin-Chung, J. et al. The interaction of deworming, improved sanitation, and household flooring with soil-transmitted helminth infection in rural Bangladesh. *PLoS Negl. Trop. Dis.* **9**, e0004256 (2015).
39. Kightlinger, L. K., Seed, J. R. & Kightlinger, M. B. *Ascaris lumbricoides* intensity in relation to environmental, socioeconomic, and behavioral determinants of exposure to infection in children from southeast Madagascar. *J. Parasitol.* **84**, 480–484 (1998).
40. Croll, N. A. & Ghadirian, E. Wormy persons: contributions to the nature and patterns of overdispersion with *Ascaris lumbricoides*, *Ancylostoma duodenale*, *Necator americanus* and *Trichuris trichiura*. *Tropical Geographical Med.* **33**, 241–248 (1981).
41. Holland, C. V. et al. Intestinal helminthiasis in relation to the socioeconomic environment of Panamanian children. *Soc. Sci. Med.* **26**, 209–213 (1988).
42. Haswell-Elkins, M., Elkins, D. & Anderson, R. M. The influence of individual, social group and household factors on the distribution of *Ascaris lumbricoides* within a community and implications for control strategies. *Parasitology* **98**, 125–134 (1989).
43. Holland, C. V. et al. The epidemiology of *Ascaris lumbricoides* and other soil-transmitted helminths in primary school children from Ille-Ife, Nigeria. *Parasitology* **99**, 275–285 (1989).
44. Nogueira, D. S. et al. Multiple exposures to *Ascaris suum* induce tissue injury and mixed Th2/Th17 immune response in mice. *PLoS Negl. Trop. Dis.* **10**, e0004382 (2016).
45. Chan, L., Bundy, D. A. & Kan, S. P. Genetic relatedness as a determinant of predisposition to *Ascaris lumbricoides* and *Trichuris trichiura* infection. *Parasitology* **108**, 77–80 (1994).
46. Williams-Blangero, S. et al. Genetic analysis of susceptibility to infection with *Ascaris lumbricoides*. *Am. J. Tropical Med. Hyg.* **60**, 921–926 (1999).
47. Williams-Blangero, S. et al. Genes on chromosomes 1 and 13 have significant effects on *Ascaris* infection. *Proc. Natl Acad. Sci. USA* **99**, 5533–5538 (2002).
48. Peisong, G. et al. An asthma-associated genetic variant of STAT6 predicts low burden of *Ascaris* worm infestation. *Genes. Immun.* **5**, 58–62 (2004).
49. Williams-Blangero, S. et al. Localization of multiple quantitative trait loci influencing susceptibility to infection with *Ascaris lumbricoides*. *J. Infect. Dis.* **197**, 66–71 (2008).
50. Acevedo, N. et al. Association between total immunoglobulin E and antibody responses to naturally acquired *Ascaris lumbricoides* infection and polymorphisms of immune system-related LIG4, TNFSF13B and IRS2 genes. *Clin. Exp. Immunol.* **157**, 282–290 (2009).
51. Dold, C. & Holland, C. V. Investigating the underlying mechanism of resistance to *Ascaris* infection. *Microbes Infect.* **13**, 624–631 (2011).
52. O'Sullivan, J. D. B. et al. X-ray micro-computed tomography (muCT): an emerging opportunity in parasite imaging. *Parasitology* **145**, 848–854 (2018).
53. Starborg, T. et al. Experimental steering of electron microscopy studies using prior X-ray computed tomography. *Ultramicroscopy* **201**, 58–67 (2019).
54. Hayes, K. S. et al. Exploitation of the intestinal microflora by the parasitic nematode *Trichuris muris*. *Science* **328**, 1391–1394 (2010).
55. Cliffe, L. J. & Grenis, R. K. The *Trichuris muris* system: a paradigm of resistance and susceptibility to intestinal nematode infection. *Adv. Parasitol.* **57**, 255–307 (2004).
56. Hurst, R. J. & Else, K. J. *Trichuris muris* research revisited: a journey through time. *Parasitology* **140**, 1325–1339 (2013).
57. Pike, E. H. Egg output of *Trichuris muris* (Schrank, 1788). *J. Parasitol.* **55**, 1046–1049 (1969).
58. Eichenberger, R. M. et al. Characterization of *Trichuris muris* secreted proteins and extracellular vesicles provides new insights into host-parasite communication. *J. Extracell. Vesicles* **7**, 1428004 (2018).
59. Bancroft, A. J. et al. The major secreted protein of the whipworm parasite tethers to matrix and inhibits interleukin-13 function. *Nat. Commun.* **10**, 2344 (2019).
60. Leroux, L. P. et al. Analysis of the *Trichuris suis* excretory/secretory proteins as a function of life cycle stage and their immunomodulatory properties. *Sci. Rep.* **8**, 15921 (2018).
61. Faulkner, H. et al. Age- and infection intensity-dependent cytokine and antibody production in human trichuriasis: the importance of IgE. *J. Infect. Dis.* **185**, 665–672 (2002).
62. de Ruiter, K. et al. Helminth infections drive heterogeneity in human type 2 and regulatory cells. *Sci. Transl. Med.* **12**, eaaw3703 (2020).
63. Turner, J. D. et al. Th2 cytokines are associated with reduced worm burdens in a human intestinal helminth infection. *J. Infect. Dis.* **188**, 1768–1775 (2003).
64. Dige, A. et al. Mucosal and systemic immune modulation by *Trichuris trichiura* in a self-infected individual. *Parasite Immunol.* **39**, e12394 (2017).
65. Broadhurst, M. J. et al. IL-22+ CD4+ T cells are associated with therapeutic *Trichuris trichiura* infection in an ulcerative colitis patient. *Sci. Transl. Med.* **2**, 60ra88 (2010).
66. Kringel, H., Iburg, T., Dawson, H., Aasted, B. & Roepstorff, A. A time course study of immunological responses in *Trichuris suis* infected pigs demonstrates induction of a local type 2 response associated with worm burden. *Int. J. Parasitol.* **36**, 915–924 (2006).
67. Else, K. J., Finkelman, F. D., Maliszewski, C. R. & Grenis, R. K. Cytokine-mediated regulation of chronic intestinal helminth infection. *J. Exp. Med.* **179**, 347–351 (1994).
68. Grenis, R. K. Immunity to helminths: resistance, regulation, and susceptibility to gastrointestinal nematodes. *Annu. Rev. Immunol.* **33**, 201–225 (2015).
69. Hadidi, S. et al. Myeloid cell-specific expression of Shp1 regulates IL-12 production and immunity to helminth infection. *Mucosal Immunol.* **5**, 535–543 (2012).
70. Artis, D. New weapons in the war on worms: identification of putative mechanisms of immune-mediated expulsion of gastrointestinal nematodes. *Int. J. Parasitol.* **36**, 723–733 (2006).
71. Klementowicz, J. E., Travis, M. A. & Grenis, R. K. *Trichuris muris*: a model of gastrointestinal parasite infection. *Semin. Immunopathol.* **34**, 815–828 (2012).
72. Sorobetea, D., Svensson-Frej, M. & Grenis, R. Immunity to gastrointestinal nematode infections. *Mucosal Immunol.* **11**, 304–315 (2018).
73. Blackwell, N. M. & Else, K. J. B cells and antibodies are required for resistance to the parasitic gastrointestinal nematode *Trichuris muris*. *Infect. Immun.* **69**, 3860–3868 (2001).

74. Perrigoue, J. G. et al. MHC class II-dependent basophil-CD4⁺ T cell interactions promote TH2 cytokine-dependent immunity. *Nat. Immunol.* **10**, 697–705 (2009).
75. Huang, X., Zeng, L. R., Chen, F. S., Zhu, J. P. & Zhu, M. H. *Trichuris suis* ova therapy in inflammatory bowel disease: a meta-analysis. *Medicine* **97**, e12087 (2018).
76. Bager, P. Use of *Trichuris suis* ova (TSO) therapy for the treatment of allergy. *Arb. Paul Ehrlich Inst. Bundesinstitut Impfstoffe Biomed. Arzneim. Langen Hess.* **97**, 128–129 (2013).
77. Schölmerich, J. et al. A randomised, double-blind, placebo-controlled trial of *Trichuris suis* ova in active Crohn's disease. *J. Crohns Colitis* **11**, 390–399 (2017).
78. Sobotkova, K. et al. Helminth therapy – from the parasite perspective. *Trends Parasitol.* **35**, 501–515 (2019).
79. Bager, P. et al. *Trichuris suis* ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. *J. Allergy Clin. Immunol.* **125**, 123–130.e1–3 (2010).
80. Hasnain, S. Z. et al. Muc5ac: a critical component mediating the rejection of enteric nematodes. *J. Exp. Med.* **208**, 893–900 (2011).
81. Hasnain, S. Z. et al. Mucin gene deficiency in mice impairs host resistance to an enteric parasitic infection. *Gastroenterology* **138**, 1763–1771 (2010). **This study provided evidence of a functional role for mucins in type 2 controlled anti-nematode immunity using the mouse model of human trichuriasis.**
82. Foth, B. J. et al. Whipworm genome and dual-species transcriptome analyses provide molecular insights into an intimate host-parasite interaction. *Nat. Genet.* **46**, 693–700 (2014).
83. Khan, W. I. et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. *Infect. Immun.* **71**, 2430–2438 (2003).
84. Cliffe, L. J. et al. Accelerated intestinal epithelial cell turnover: a new mechanism of parasite expulsion. *Science* **308**, 1463–1465 (2005).
85. Jarrett, E. E. & Miller, H. R. Production and activities of IgE in helminth infection. *Prog. Allergy* **31**, 178–233 (1982).
86. Else, K. J. & Grecnis, R. K. Antibody-independent effector mechanisms in resistance to the intestinal nematode parasite *Trichuris muris*. *Infect. Immun.* **64**, 2950–2954 (1996).
87. Constant, S., Schweitzer, N., West, J., Ranney, P. & Bottomly, K. B lymphocytes can be competent antigen-presenting cells for priming CD4⁺ T cells to protein antigens in vivo. *J. Immunol.* **155**, 3734–3741 (1995).
88. Lund, F. E., Garvy, B. A., Randall, T. D. & Harris, D. P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. *Curr. Dir. Autoimmun.* **8**, 25–54 (2005).
89. Wojciechowski, W. et al. Cytokine-producing effector B cells regulate type 2 immunity to *H. polygyrus*. *Immunity* **30**, 421–433 (2009).
90. Schopf, L. R., Hoffmann, K. F., Cheever, A. W., Urban, J. F. Jr. & Wynn, T. A. IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. *J. Immunol.* **168**, 2383–2392 (2002).
91. Duque-Correa, M. A. et al. Exclusive dependence of IL-10Rα signalling on intestinal microbiota homeostasis and control of whipworm infection. *PLoS Pathog.* **15**, e1007265 (2019).
92. Houlden, A. et al. Chronic *Trichuris muris* infection in c57bl/6 mice causes significant changes in host microbiota and metabolome: effects reversed by pathogen clearance. *PLoS One* **10**, e0125945 (2015).
93. Holm, J. B. et al. Chronic *Trichuris muris* infection decreases diversity of the intestinal microbiota and concomitantly increases the abundance of lactobacilli. *PLoS One* **10**, e0125495 (2015).
94. Li, R. W. et al. Alterations in the porcine colon microbiota induced by the gastrointestinal nematode *Trichuris suis*. *Infect. Immun.* **80**, 2150–2157 (2012).
95. Wu, S. et al. Worm burden-dependent disruption of the porcine colon microbiota by *Trichuris suis* infection. *PLoS One* **7**, e35470 (2012).
96. Lee, S. C. et al. Helminth colonization is associated with increased diversity of the gut microbiota. *PLoS Negl. Trop. Dis.* **8**, e2880 (2014).
97. Cooper, P. et al. Patent human infections with the whipworm, *Trichuris trichiura*, are not associated with alterations in the faecal microbiota. *PLoS One* **8**, e76573 (2013).
98. White, E. C. et al. Manipulation of host and parasite microbiotas: survival strategies during chronic nematode infection. *Sci. Adv.* **4**, eaap7399 (2018).
99. Stephenson, L. S. & Holland, C. *The Impact of Helminth Infections on Human Nutrition: schistosomes and soil-transmitted helminths* 93 (Taylor and Francis, 1987).
100. Wong, M. S. & Bundy, D. A. Quantitative assessment of contamination of soil by the eggs of *Ascaris lumbricoides* and *Trichuris trichiura*. *Trans. R. Soc. Tropical Med. Hyg.* **84**, 567–570 (1990).
101. Douvres, F. W. & Urban, J. F. Jr. Factors contributing to the in vitro development of *Ascaris suum* from second-stage larvae to mature adults. *J. Parasitol.* **69**, 549–558 (1983).
102. Fagerholm, H. P., Nansen, P., Roepstorff, A., Frandsen, F. & Eriksen, L. Differentiation of cuticular structures during the growth of the third-stage larva of *Ascaris suum* (Nematoda, Ascaridoidea) after emerging from the egg. *J. Parasitol.* **86**, 421–427 (2000).
103. Pilitt, P. A., Lichtenfels, J. R., Tromba, F. G. & Madden, P. A. Differentiation of late fourth and early fifth stages of *Ascaris suum* Goetz, 1782 (Nematoda: Ascaridoidea) in swine. *Proc. Helminthol. Soc. 48*, 1–7 (1981).
104. Anderson, R. M. in *The Population Dynamics of Infectious Diseases: Theory and Applications* (ed. Anderson, R. M.) 67–108 (Springer, 1982).
105. Pawlowski, Z. S. & Arfaa, F. in *Tropical and Geographical Medicine* (eds Warren, K. S. & Mahmoud, A. A. F. 347–358 (McGraw-Hill, 1984).
106. Read, A. F. & Skorpung, A. The evolution of tissue migration by parasitic nematode larvae. *Parasitology* **111**, 359–371 (1995).
107. Javid, G. et al. *Ascaris*-induced liver abscess. *World J. Surg.* **23**, 1191–1194 (1999).
108. Ribeiro, J. D. F. G. Eosinophilic lung diseases. *Paediatr. Respir. Rev.* **3**, 278–284 (2002). **This review highlights eosinophilic lung diseases, with an emphasis on lung pathology due to parasitic infections including *Ascaris lumbricoides* infection.**
109. Hagel, I. et al. *Ascaris* reinfection of slum children: relation with the IgE response. *Clin. Exp. Immunol.* **94**, 80–83 (1993).
110. Palmer, D. R., Hall, A., Haque, R. & Anwar, K. S. Antibody isotype responses to antigens of *Ascaris lumbricoides* in a case-control study of persistently heavily infected Bangladeshi children. *Parasitology* **111**, 385–393 (1995).
111. McSharry, C., Xia, Y., Holland, C. V. & Kennedy, M. W. Natural immunity to *Ascaris lumbricoides* associated with immunoglobulin E antibody to ABA-1 allergen and inflammation indicators in children. *Infect. Immun.* **67**, 484–489 (1999).
112. King, E. M. et al. Immuno-epidemiology of *Ascaris lumbricoides* infection in a high transmission community: antibody responses and their impact on current and future infection intensity. *Parasite Immunol.* **27**, 89–96 (2005).
113. Cooper, P. J. et al. Human infection with *Ascaris lumbricoides* is associated with a polarized cytokine response. *J. Infect. Dis.* **182**, 1207–1213 (2000).
114. Jackson, J. A. et al. T helper cell type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans. *J. Infect. Dis.* **190**, 1804–1811 (2004).
115. Cooper, P. J. et al. Repeated treatments with albendazole enhance Th2 responses to *Ascaris lumbricoides*, but not to aeroallergens, in children from rural communities in the tropics. *J. Infect. Dis.* **198**, 1237–1242 (2008). **This paper presents data indicating that repeated doses of albendazole over the course of 1 year are associated with enhanced production of *Ascaris lumbricoides*-specific type 2 immunity cytokines in humans.**
116. Holland, C. V., Behnke, J. M. & Dold, C. in *Ascaris: the Neglected Parasite* (ed. Holland, C. V.) 107–125 (Elsevier, 2013).
117. Lewis, R., Behnke, J. M., Stafford, P. & Holland, C. V. Dose-dependent impact of larval *Ascaris suum* on host body weight in the mouse model. *J. Helminthol.* **83**, 1–5 (2009).
118. Deslyper, G., Holland, C. V., Colgan, T. J. & Carolan, J. C. The liver proteome in a mouse model for *Ascaris suum* resistance and susceptibility: evidence for an altered innate immune response. *Parasites Vectors* **12**, 402 (2019).
119. Lewis, R., Behnke, J. M., Stafford, P. & Holland, C. V. The development of a mouse model to explore resistance and susceptibility to early *Ascaris suum* infection. *Parasitology* **132**, 289–300 (2006).
120. Dold, C., Cassidy, J. P., Stafford, P., Behnke, J. M. & Holland, C. V. Genetic influence on the kinetics and associated pathology of the early stage (intestinal-hepatic) migration of *Ascaris suum* in mice. *Parasitology* **137**, 173–185 (2010).
121. Deslyper, G., Colgan, T. J., Cooper, A. J., Holland, C. V. & Carolan, J. C. A proteomic investigation of hepatic resistance to *Ascaris* in a murine model. *PLoS Negl. Trop. Dis.* **10**, e0004837 (2016).
122. Gazzinelli-Guimaraes, P. H. et al. Parasitological and immunological aspects of early *Ascaris* spp. infection in mice. *Int. J. Parasitol.* **43**, 697–706 (2013).
123. Weatherhead, J. E. et al. *Ascaris* larval infection and lung invasion directly induce severe allergic airway disease in mice. *Infect. Immun.* **86**, e00533-18 (2018).
124. Gazzinelli-Guimaraes, P. H. et al. Allergen sensitization drives an eosinophil-dependent arrest in lung-specific helminth development. *J. Clin. Invest.* **130**, 3686–3701 (2019).
125. Guo, L. et al. Innate immunological function of TH2 cells in vivo. *Nat. Immunol.* **16**, 1051–1059 (2015).
126. Dowling, D. J. et al. *Ascaris lumbricoides* pseudocoelomic body fluid induces a partially activated dendritic cell phenotype with Th2 promoting ability in vivo. *Int. J. Parasitol.* **41**, 255–261 (2011).
127. Favoretto, B. C. et al. High molecular weight components containing N-linked oligosaccharides of *Ascaris suum* extract inhibit the dendritic cells activation through DC-SIGN and MR. *Mol. Immunol.* **87**, 33–46 (2017).
128. Almeida, S., Nejsun, P. & Williams, A. R. Modulation of human macrophage activity by *Ascaris* antigens is dependent on macrophage polarization state. *Immunobiology* **223**, 405–412 (2018).
129. Titz, T. O. et al. *Ascaris suum* infection modulates inflammation: implication of CD4(+) CD25(hi) Foxp3(+) T cells and IL-10. *Parasite Immunol.* **39**, e12453 (2017).
130. Nascimento, W. C. et al. Immunomodulation of liver injury by *Ascaris suum* extract in an experimental model of autoimmune hepatitis. *Parasitol. Res.* **113**, 3309–3317 (2014).
131. Paterson, J. C., Garside, P., Kennedy, M. W. & Lawrence, C. E. Modulation of a heterologous immune response by the products of *Ascaris suum*. *Infect. Immun.* **70**, 6058–6067 (2002).
132. Gazzinelli-Guimaraes, P. H. et al. Concomitant helminth infection downmodulates the Vaccinia virus-specific immune response and potentiates virus-associated pathology. *Int. J. Parasitol.* **47**, 1–10 (2017).
133. Suzuki, M. et al. Presensitization to *Ascaris* antigens promotes induction of mite-specific IgE upon mite antigen inhalation in mice. *Allergol. Int.* **65**, 44–51 (2016).
134. Jungersen, G., Fagerholm, H. P., Nansen, P. & Eriksen, L. Development of patent *Ascaris suum* infections in pigs following intravenous administration of larvae hatched in vitro. *Parasitology* **119**, 503–508 (1999).
135. Masure, D. et al. The intestinal expulsion of the roundworm *Ascaris suum* is associated with eosinophils, intra-epithelial T cells and decreased intestinal transit time. *PLoS Negl. Trop. Dis.* **7**, e2588 (2013).
136. Schwartz, B. A. J. *Ascaris* larvae as a cause of liver and lung lesions in swine. *J. Parasitol.* **19**, 17–24 (1932).
137. Copeman, D. B. & Gaafar, S. M. Sequential development of hepatic lesions of ascariidosis in colostrum-deprived pigs. *Aust. Vet. J.* **48**, 263–268 (1972).
138. Perez, J., Garcia, P. M., Mozos, E., Bautista, M. J. & Carrasco, L. Immunohistochemical characterization of hepatic lesions associated with migrating larvae of *Ascaris suum* in pigs. *J. Comp. Pathol.* **124**, 200–206 (2011).
139. Masure, D. et al. A role for eosinophils in the intestinal immunity against infective *Ascaris suum* larvae. *PLoS Negl. Trop. Dis.* **7**, e2138 (2013).
140. Ashraf, M., Urban, J. F. Jr., Lee, T. D. & Lee, C. M. Characterization of isolated porcine intestinal mucosal mast cells following infection with *Ascaris suum*. *Vet. Parasitol.* **29**, 143–158 (1988).
141. Uston, P. I., Urban, J. F. Jr., Ashraf, M., Lee, C. M. & Ampy, F. R. L3L4ES antigen and secretagogues induce histamine release from porcine peripheral blood basophils after *Ascaris suum* infection. *Parasitol. Res.* **100**, 603–611 (2007).

142. Urban, J. F. Jr., Alizadeh, H. & Romanowski, R. D. *Ascaris suum*: development of intestinal immunity to infective second-stage larvae in swine. *Exp. Parasitol.* **66**, 66–77 (1988).
143. Wang, Y. et al. *Ascaris suum* infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome. *Int. J. Parasitol.* **49**, 247–256 (2019).
144. McCraw, B. M. & Greenway, J. A. *Ascaris suum* infection in calves. 3. Pathology. *Can. J. Comp. Med.* **34**, 247–255 (1970).
145. Fallis, A. M. *Ascaris lumbricoides* infection in guinea pigs with special reference to eosinophilia and resistance. *Can. J. Res.* **26**, 307–327 (1948).
146. Arean, V. M. & Crandall, C. A. The effect of immunization on the fate of injected second stage *Ascaris lumbricoides* larvae in the rabbit. *Am. J. Tropical Med. Hyg.* **11**, 369–379 (1962).
147. Cho, S. et al. Migration behaviour and pathogenesis of five ascarid nematode species in the Mongolian gerbil *Meriones unguiculatus*. *J. Helminthol.* **81**, 43–47 (2007).
148. Weiszer, I., Patterson, R. & Pruzansky, J. J. *Ascaris* hypersensitivity in the rhesus monkey: I. A model for the study of immediate type hypersensitivity in the primate. *J. Allergy* **41**, 14–22 (1968).
149. Pritchard, D. I. et al. Laboratory infection of primates with *Ascaris suum* to provide a model of allergic bronchoconstriction. *Clin. Exp. Immunol.* **54**, 469–476 (1983).
150. Patterson, R., Harris, K. E. & Pruzansky, J. J. Induction of IgE-mediated cutaneous, cellular, and airway reactivity in rhesus monkeys by *Ascaris suum* infection. *J. Lab. Clin. Med.* **101**, 864–872 (1983).
151. Layrisse, M., Aparcedo, L., Martinez-Torres, C. & Roche, M. Blood loss due to infection with *Trichuris trichiura*. *Am. J. Trop. Med. Hyg.* **16**, 613–619 (1967).
152. Ramdath, D. D., Simeon, D. T., Wong, M. S. & Grantham-McGregor, S. M. Iron status of schoolchildren with varying intensities of *Trichuris trichiura* infection. *Parasitology* **110**, 347–351 (1995).
153. Robertson, L. J., Crompton, D. W., Sanjur, D. & Nesheim, M. C. Haemoglobin concentrations and concomitant infections of hookworm and *Trichuris trichiura* in Panamanian primary schoolchildren. *Trans. R. Soc. Trop. Med. Hyg.* **86**, 654–656 (1992).
154. Gyorkos, T. W., Gilbert, N. L., Larocque, R. & Casapia, M. *Trichuris* and hookworm infections associated with anaemia during pregnancy. *Trop. Med. Int. Health* **16**, 531–537 (2011).
155. Cooper, E. S. & Bundy, D. A. *Trichuris* is not trivial. *Parasitol. Today* **4**, 301–306 (1988).
156. Wolfe, M. S. *Oxyuris*, *Trichostrongylus* and *Trichuris*. *Clin. Gastroenterol.* **7**, 201–217 (1978).
157. Khuroo, M. S., Khuroo, M. S. & Khuroo, N. S. *Trichuris* dysentery syndrome: a common cause of chronic iron deficiency anemia in adults in an endemic area (with videos). *Gastrointest. Endoscopy* **71**, 200–204 (2010).
158. Stephenson, L. S., Holland, C. V. & Cooper, E. S. The public health significance of *Trichuris trichiura*. *Parasitology* **121**, S73–S95 (2000).
159. Kaminsky RG, C. R., & Flores, C. A. Growth retardation and severe anemia in children with *Trichuris* dysenteric syndrome. *Asian Pac. J. Trop. Biomed.* **5**, 591–597 (2015).
160. Al-Mekhlafi, M. H. et al. Anaemia and iron deficiency anaemia among aboriginal schoolchildren in rural Peninsular Malaysia: an update on a continuing problem. *Trans. R. Soc. Tropical Med. Hyg.* **102**, 1046–1052 (2008).
161. Sarkar, M., Mahesh, D. M. & Madabhavi, I. Digital clubbing. *Lung India* **29**, 354–362 (2012).
162. Cooper, E. S., Bundy, D. A. & Henry, F. J. Chronic dysentery, stunting, and whipworm infestation. *Lancet* **2**, 280–281 (1986).
163. MacDonald, T. T. et al. Immunoepidemiology of intestinal helminthic infections. 3. Mucosal macrophages and cytokine production in the colon of children with *Trichuris trichiura* dysentery. *Trans. R. Soc. Tropical Med. Hyg.* **88**, 265–268 (1994).
164. Ok, K. S. et al. *Trichuris trichiura* infection diagnosed by colonoscopy: case reports and review of literature. *Korean J. Parasitol.* **47**, 275–280 (2009).
165. Jha, A. K., Goenka, M. K. & Suchismita, A. Clinical correlates of trichuriasis diagnosed at colonoscopy. *Indian J. Gastroenterol.* **36**, 420–423 (2017).
166. Martin, I. et al. Dynamic changes in human-gut microbiome in relation to a placebo-controlled anthelmintic trial in Indonesia. *PLoS Negl. Trop. Dis.* **12**, e0006620 (2018).
167. Gilman, R. H. et al. The adverse consequences of heavy *Trichuris* infection. *Trans. R. Soc. Tropical Med. Hyg.* **77**, 432–438 (1983).
168. Shin, J. L., Gardiner, G. W., Deitel, W. & Kandel, G. Does whipworm increase the pathogenicity of *Campylobacter jejuni*? A clinical correlate of an experimental observation. *Can. J. Gastroenterol.* **18**, 175–177 (2004).
169. Jensen, L. A., Marlin, J. W., Dyck, D. D. & Laubach, H. E. Prevalence of multi-gastrointestinal infections with helminth, protozoan and *Campylobacter* spp. in Guatemalan children. *J. Infect. Dev. Ctries.* **3**, 229–234 (2009).
170. Mansfield, L. S. et al. Enhancement of disease and pathology by synergy of *Trichuris suis* and *Campylobacter jejuni* in the colon of immunologically naive swine. *Am. J. Tropical Med. Hyg.* **68**, 70–80 (2003).
171. Croll, N. A., Anderson, R. M., Gyorkos, T. W. & Ghadirian, E. The population biology and control of *Ascaris lumbricoides* in a rural community in Iran. *Trans. R. Soc. Tropical Med. Hyg.* **76**, 187–197 (1982).
172. Thein, H., Than, S., Htay Htay, A., Myint, L. & Thein Maung, M. Epidemiology and transmission dynamics of *Ascaris lumbricoides* in Okpo village, rural Burma. *Trans. R. Soc. Tropical Med. Hyg.* **78**, 497–504 (1984).
173. Löffler, W. Transient lung infiltrations with blood eosinophilia. *Int. Arch. Allergy Appl. Immunol.* **8**, 54–59 (1956).
174. Khuroo, N. S., Khuroo, M. S. & Khuroo, M. S. Gastric ascariasis presenting as unique dyspeptic symptoms in an endemic area. *Am. J. Gastroenterol.* **105**, 1675–1677 (2010).
175. Das, A. K. Hepatic and biliary ascariasis. *J. Glob. Infect. Dis.* **6**, 65–72 (2014).
176. Khuroo, M. S. Ascariasis. *Gastroenterol. Clin. North. Am.* **25**, 553–577 (1996).
177. Efem, S. E. *Ascaris lumbricoides* and intestinal perforation. *Br. J. Surg.* **74**, 643–644 (1987).
178. Paul, M. The movements of the adult *Ascaris lumbricoides*. *Br. J. Surg.* **59**, 437–442 (1972).
179. Villamizar, E., Mendez, M., Bonilla, E., Varon, H. & de Onatra, S. *Ascaris lumbricoides* infestation as a cause of intestinal obstruction in children: experience with 87 cases. *J. Pediatric Surg.* **31**, 201–204 (1996).
180. Nokes, C. & Bundy, D. A. Does helminth infection affect mental processing and educational achievement? *Parasitol. Today* **10**, 14–18 (1994).
- This article reviews the evidence linking helminth infections with impaired cognitive function and the difficulties associated with such studies.**
181. Symons, L. E. Anorexia: occurrence, pathophysiology, and possible causes in parasitic infections. *Adv. Parasitol.* **24**, 103–133 (1985).
182. Stephenson, L. S. The contribution of *Ascaris lumbricoides* to malnutrition in children. *Parasitology* **81**, 221–233 (1980).
183. Katz, N., Chaves, A. & Pellegrino, J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. *Rev. Inst. Med. Trop. Sao Paulo* **14**, 397–400 (1972).
184. World Health Organization. *Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee* (WHO, 2002).
185. Nikolay, B., Brooker, S. J. & Pullan, R. L. Sensitivity of diagnostic tests for human soil-transmitted helminth infections: a meta-analysis in the absence of a true gold standard. *Int. J. Parasitol.* **44**, 765–774 (2014).
186. Bogoch, I. I. et al. Mobile phone microscopy for the diagnosis of soil-transmitted helminth infections: a proof-of-concept study. *Am. J. Tropical Med. Hyg.* **88**, 626–629 (2013).
- This paper explores the use of mobile phone microscopy as a novel method for point-of-care diagnosis of soil-transmitted helminth infections.**
187. Moser, W. et al. Diagnostic comparison between FECPAKG2 and the Kato-Katz method for analyzing soil-transmitted helminth eggs in stool. *PLoS Neglected Tropical Dis.* **12**, e0006562 (2018).
188. Arndt, M. B. et al. Impact of helminth diagnostic test performance on estimation of risk factors and outcomes in HIV-positive adults. *PLoS One* **8**, e81915 (2013).
189. Easton, A. V. et al. Multi-parallel qPCR provides increased sensitivity and diagnostic breadth for gastrointestinal parasites of humans: field-based inferences on the impact of mass deworming. *Parasites Vectors* **9**, 38 (2016).
190. Liu, J. et al. A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogens. *J. Clin. Microbiol.* **51**, 472–480 (2013).
191. Mationg, M. L. S. et al. Status of soil-transmitted helminth infections in schoolchildren in Laguna Province, the Philippines: determined by parasitological and molecular diagnostic techniques. *PLoS Negl. Trop. Dis.* **11**, e0006022 (2017).
192. O'Connell, E. M. & Nutman, T. B. Molecular diagnostics for soil-transmitted helminths. *Am. J. Tropical Med. Hyg.* **95**, 508–513 (2016).
193. Phuphisut, O. et al. Triplex polymerase chain reaction assay for detection of major soil-transmitted helminths, *Ascaris lumbricoides*, *Trichuris trichiura*, *Necator americanus*, in fecal samples. *Southeast. Asian J. Tropical Med. Public. Health* **45**, 267–275 (2014).
194. Llewellyn, S. et al. Application of a multiplex quantitative PCR to assess prevalence and intensity of intestinal parasite infections in a controlled clinical trial. *PLoS Negl. Trop. Dis.* **10**, e0004380 (2016).
195. Cunningham, L. J. et al. Developing a real-time PCR assay based on multiplex high-resolution melt-curve analysis: a pilot study in detection and discrimination of soil-transmitted helminth and schistosome species. *Parasitology* **145**, 1733–1738 (2018).
196. Mejia, R. et al. A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. *Am. J. Tropical Med. Hyg.* **88**, 1041–1047 (2013).
197. Pilotte, N. et al. Improved PCR-based detection of soil transmitted helminth infections using a next-generation sequencing approach to assay design. *PLoS Negl. Trop. Dis.* **10**, e0004578 (2016).
198. Rashwan, N., Diawara, A., Scott, M. E. & Pritchard, R. K. Isothermal diagnostic assays for the detection of soil-transmitted helminths based on the SmartAmp2 method. *Parasites Vectors* **10**, 496 (2017).
199. Schrader, C., Schielke, A., Ellerbroek, L. & John, R. PCR inhibitors-occurrence, properties and removal. *J. Appl. Microbiol.* **113**, 1014–1026 (2012).
200. World Health Organization. *Prevention and control of intestinal parasitic infections: report of a WHO expert committee* (WHO, 1987).
201. Marocco, C., Bangert, M., Joseph, S. A., Fitzpatrick, C. & Montresor, A. Preventive chemotherapy in one year reduces by over 80% the number of individuals with soil-transmitted helminthiasis causing morbidity: results from meta-analysis. *Trans. R. Soc. Tropical Med. Hyg.* **111**, 12–17 (2017).
202. Bah, Y. M. et al. Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions. *Infect. Dis. Poverty* **8**, 41 (2019).
203. Shumbej, T. et al. Impact of annual preventive mass chemotherapy for soil-transmitted helminths among primary school children in an endemic area of Gurage zone: a prospective cross-sectional study. *Res. Rep. Tropical Med.* **10**, 109–118 (2019).
204. Bartram, J. & Cairncross, S. Hygiene, sanitation, and water: forgotten foundations of health. *PLoS Med.* **7**, e1000367 (2010).
205. Fewtrell, L. et al. Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis. *Lancet. Infect. Dis.* **5**, 42–52 (2005).
- This article provides a systematic review and meta-analysis summarizing the importance of water, sanitation and hygiene (WASH) interventions in the control of soil transmitted helminth infections.**
206. Cairncross, S. et al. Water, sanitation and hygiene for the prevention of diarrhoea. *Int. J. Epidemiol.* **39** (Suppl 1), i193–i205 (2010).
207. Strunz, E. C. et al. Water, sanitation, hygiene, and soil-transmitted helminth infection: a systematic review and meta-analysis. *PLoS Med.* **11**, e1001620 (2014).
208. Vaz Nery, S. et al. The role of water, sanitation and hygiene interventions in reducing soil-transmitted helminths: interpreting the evidence and identifying next steps. *Parasites Vectors* **12**, 273 (2019).
209. Freeman, M. C. et al. Challenges and opportunities for control and elimination of soil-transmitted helminth infection beyond 2020. *PLoS Negl Trop Dis* **13**, e0007201 (2019).
210. World Health Organization. *2030 targets for soil-transmitted helminthiasis control programmes* (WHO, 2020).
211. Turner, K. J., Fisher, E. H. & McWilliam, A. S. Homology between roundworm (*Ascaris*) and hookworm (*N. americanus*) antigens detected by human IgE

- antibodies. *Australian J. Exp. Biol. Med. Sci.* **58**, 249–257 (1980).
212. Correa-Oliveira, R. et al. Human antibody responses against schistosoma antigens. I. Antibodies from patients with *Ancylostoma*, *Ascaris lumbricoides* or *Schistosoma mansoni* infections react with schistosome antigens. *Am. J. Tropical Med. Hyg.* **38**, 348–355 (1988).
 213. Betschart, B., Marti, S. & Glaser, M. Antibodies against the cuticlin of *Ascaris suum* cross-react with epicuticular structures of filarial parasites. *Acta Tropica* **47**, 331–338 (1990).
 214. Cuellar, C., Fenoy, S. & Guillen, J. L. Cross-reactions of sera from *Toxascaris leonina* and *Ascaris suum* infected mice with *Toxocara canis*, *Toxascaris leonina* and *Ascaris suum* antigens. *Int. J. Parasitol.* **25**, 731–739 (1995).
 215. Santos, A. B. et al. Cross-reactive IgE antibody responses to tropomyosins from *Ascaris lumbricoides* and cockroach. *J. Allergy Clin. Immunol.* **121**, 1040–1046.e1 (2008).
 216. Caraballo, L. & Acevedo, N. Allergy in the tropics: the impact of cross-reactivity between mites and *Ascaris*. *Front. Biosci.* **3**, 51–64 (2011).
 217. Elsemore, D. A. et al. Enzyme-linked immunosorbent assay for coproantigen detection of *Trichuris vulpis* in dogs. *J. Veterinary Diagn. Invest.* **26**, 404–411 (2014).
 218. Martinez-Perez, J. M., Vandekerckhove, E., Vlaminc, J., Geldhof, P. & Martinez-Valladares, M. Serological detection of *Ascaris suum* at fattening pig farms is linked with performance and management indices. *Veterinary Parasitol.* **248**, 33–38 (2017).
 219. Geng, J., Elsemore, D. A., Oudin, N. & Ketzis, J. K. Diagnosis of feline whipworm infection using a coproantigen ELISA and the prevalence in feral cats in southern Florida. *Veterinary Parasitol. Regional Stud. Rep.* **14**, 181–186 (2018).
 220. Lassen, B. et al. Anti-*Ascaris suum* IgG antibodies in fattening pigs with different respiratory conditions. *Veterinary Parasitol.* **265**, 85–90 (2019).
 221. Yoshida, A., Kikuchi, T., Nakagaki, S. & Maruyama, H. Optimal ELISA antigen for the diagnosis of *Ascaris suum* infection in humans. *Parasitology Res.* **115**, 4701–4705 (2016).
 222. Lopes, C. A. et al. Anti-*Ascaris suum* immunoglobulin Y as a novel biotechnological tool for the diagnosis of human ascariasis. *J. Helminthol.* **94**, e71 (2019).
 223. Gazzinelli-Guimaraes, A. C. et al. IgG induced by vaccination with *Ascaris suum* extracts is protective against infection. *Front. Immunol.* **9**, 2535 (2018).
 224. Robinson, K., Bellaby, T. & Wakelin, D. Efficacy of oral vaccination against the murine intestinal parasite *Trichuris muris* is dependent upon host genetics. *Infect. Immun.* **63**, 1762–1766 (1995).
 225. Dixon, H., Little, M. C. & Else, K. J. Characterisation of the protective immune response following subcutaneous vaccination of susceptible mice against *Trichuris muris*. *Int. J. Parasitol.* **40**, 683–693 (2010).
 226. Zhan, B. et al. Advancing a multivalent 'Pan-anthelmintic' vaccine against soil-transmitted nematode infections. *Expert. Rev. Vaccines* **13**, 321–331 (2014).
 227. World Health Organization. *Preventive chemotherapy in human helminthiasis. Coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers* (WHO, 2006).
 228. Oliaro, P. et al. Potential drug development candidates for human soil-transmitted helminthiasis. *PLoS Negl. Trop. Dis.* **5**, e1138 (2011).
 229. Palmeirim, M. S., Ame, S. M., Ali, S. M., Hattendorf, J. & Keiser, J. Efficacy and safety of a single dose versus a multiple dose regimen of mebendazole against hookworm infections in children: a randomised, double-blind trial. *EClinicalMedicine* **1**, 7–13 (2018).
 230. World Health Organization. *WHO model list of essential medicines* (WHO, 2017).
 231. Moser, W., Schindler, C. & Keiser, J. in *Highlighting Operational and Implementation Research for Control of Helminthiasis* (ed. Keiser, J.) 91–115 (Academic Press, 2019).
 232. Palmeirim, M. S. et al. Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: a systematic review, meta-analysis and individual patient data analysis. *PLoS Negl. Trop. Dis.* **12**, e0006458 (2018).
 233. Patel, C. et al. Efficacy and safety of ivermectin and albendazole co-administration in school-aged children and adults infected with *Trichuris trichiura*: study protocol for a multi-country randomized controlled double-blind trial. *BMC Infect. Dis.* **19**, 262 (2019).
 234. Opoku, N. O. et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. *Lancet* **392**, 1207–1216 (2018).
 235. Keller, L. et al. Efficacy and safety of ascending dosages of moxidectin and moxidectin-albendazole against *Trichuris trichiura* in adolescents: a randomized controlled trial. *Clin. Infect. Dis.* **70**, 1193–1201 (2020).
 236. Wimmersberger, D. et al. Efficacy and safety of ivermectin against *Trichuris trichiura* in preschool- and school-aged children: a randomized controlled dose-finding trial. *Clin. Infect. Dis.* **67**, 1247–1255 (2018).
 237. Kopp, S. & Keiser, J. in *Kucers' The Use of Antibiotics: a Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs*, 7th edn (ed. Grayson, M. L. et al.) 3381–3384 (CRC Press, 2017).
 238. Moser, W. et al. Efficacy and tolerability of triple drug therapy with albendazole, pyrantel pamoate, and oxfantel pamoate compared with albendazole plus oxfantel pamoate, pyrantel pamoate plus oxfantel pamoate, and mebendazole plus pyrantel pamoate and oxfantel pamoate against hookworm infections in school-aged children in Laos: a randomised, single-blind trial. *Lancet. Infect. Dis.* **18**, 729–737 (2018).
 239. Krucken, J. et al. Anthelmintic cyclooctadepsipeptides: complex in structure and mode of action. *Trends Parasitol.* **28**, 385–394 (2012).
 240. Karpstein, T. et al. Evaluation of emodepside in laboratory models of human intestinal nematode and schistosome infections. *Parasites Vectors* **12**, 226 (2019).
 241. Matamoros, G. et al. High endemicity of soil-transmitted helminths in a population frequently exposed to albendazole but no evidence of antiparasitic resistance. *Top. Med. Infect. Dis.* **4**, 73 (2019).
 242. Moser, W., Schindler, C. & Keiser, J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. *BMJ* **358**, j4307 (2017).
 243. Khuroo, M. S., Rather, A. A., Khuroo, N. S. & Khuroo, M. S. Hepatobiliary and pancreatic ascariasis. *World J. Gastroenterol.* **22**, 7507–7517 (2016).
 244. Alhamid, A. et al. Successful elimination of gallbladder ascariasis by conservative therapy, followed by cholecystectomy due to developing cholecystitis. *Case Rep. Gastrointest. Med.* **2018**, 5831257 (2018).
 245. Gupta, S. et al. *Ascaris lumbricoides*: an unusual aetiology of gastric perforation. *J. Surg. Case Rep.* **2012**, rjs008 (2012).
 246. Campbell, S. J. et al. Complexities and perplexities: a critical appraisal of the evidence for soil-transmitted helminth infection-related morbidity. *PLoS Negl. Trop. Dis.* **10**, e0004566 (2016).
 247. Taylor-Robinson, D. C., Maayan, N., Donegan, S., Chaplin, M. & Garner, P. Public health deworming programmes for soil-transmitted helminths in children living in endemic areas. *Cochrane Database Syst. Rev.* **9**, CD000371 (2019).
 248. Welch, V. A. et al. Mass deworming to improve developmental health and wellbeing of children in low-income and middle-income countries: a systematic review and network meta-analysis. *Lancet. Glob. Health* **5**, e40–e50 (2017).
 249. Taylor-Robinson, D. C., Maayan, N., Soares-Weiser, K., Donegan, S. & Garner, P. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance. *Cochrane Database of Syst. Rev.* **7**, CD000371 (2015).
 250. Pabalan, N. et al. Soil-transmitted helminth infection, loss of education and cognitive impairment in school-aged children: a systematic review and meta-analysis. *PLoS Negl. Trop. Dis.* **12**, e0005523 (2018).
 251. Yap, P., Utzinger, J., Hattendorf, J. & Steinmann, P. Influence of nutrition on infection and re-infection with soil-transmitted helminths: a systematic review. *Parasites Vectors* **7**, 229 (2014).
 252. Cooper, E. S., Duff, E. M., Howell, S. & Bundy, D. A. 'Catch-up' growth velocities after treatment for *Trichuris* dysentery syndrome. *Trans. R. Soc. Tropical Med. Hyg.* **89**, 653 (1995).
 253. Cooper, E. S., Bundy, D. A., MacDonald, T. T. & Golden, M. H. Growth suppression in the *Trichuris* dysentery syndrome. *Eur. J. Clin. Nutr.* **44**, 285–291 (1990).
 254. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1789–1858 (2018).
 255. The World Bank. Decline of global extreme poverty continues but has slowed: World Bank. *The World Bank* <https://www.worldbank.org/en/news/press-release/2018/09/19/decline-of-global-extreme-poverty-continues-but-has-slowed-world-bank> (2018).
 256. Brooker, S. Estimating the global distribution and disease burden of intestinal nematode infections: adding up the numbers—a review. *Int. J. Parasitol.* **40**, 1137–1144 (2010).
 257. Gardner, J. M., Grantham-McGregor, S. & Baddeley, A. *Trichuris trichiura* infection and cognitive function in Jamaican school children. *Ann. Tropical Med. Parasitol.* **90**, 55–63 (1996).
 258. Simeon, D. T., Grantham-McGregor, S. M., Callender, J. E. & Wong, M. S. Treatment of *Trichuris trichiura* infections improves growth, spelling scores and school attendance in some children. *J. Nutr.* **125**, 1875–1883 (1995).
 259. Ahmed, A. et al. Soil-transmitted helminthiasis: a critical but neglected factor influencing school participation of Aboriginal children in rural Malaysia. *Parasitology* **139**, 802–808 (2012).
 260. Callender, J., Grantham-McGregor, S., Walker, S. & Cooper, E. Developmental levels and nutritional status of children with the *Trichuris* dysentery syndrome. *Trans. R. Soc. Tropical Med. Hyg.* **87**, 528–529 (1993).
 261. Stephenson, L. S., Latham, M. C., Adams, E. J., Kinoti, S. N. & Pertet, A. Physical fitness, growth and appetite of Kenyan school boys with hookworm, *Trichuris trichiura* and *Ascaris lumbricoides* infections are improved four months after a single dose of albendazole. *J. Nutr.* **123**, 1036–1046 (1993).
 262. Lenk, E. J., Redekop, W. K., Luyendijk, M., Rijnsburger, A. J. & Severens, J. L. Productivity loss related to neglected tropical diseases eligible for preventive chemotherapy: a systematic literature review. *PLoS Negl. Trop. Dis.* **10**, e0004397 (2016).
 263. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1859–1922 (2018).
 264. Gyorkos, T. W. et al. The right to deworming: the case for girls and women of reproductive age. *PLoS Negl. Trop. Dis.* **12**, e0006740 (2018).
 265. Galgamuwa, L. S., Iddawala, D. & Dharmaratne, S. D. Prevalence and intensity of *Ascaris lumbricoides* infections in relation to undernutrition among children in a tea plantation community, Sri Lanka: a cross-sectional study. *BMC Pediatrics* **18**, 13 (2018).
 266. Drake, L. J., Jukes, M. C. H., Sternberg, R. J. & Bundy, D. A. P. Geohelminth infections (ascariasis, trichuriasis and hookworm): cognitive and developmental impacts. *Semin. Pediatric Infect. Dis.* **11**, 245–251 (2000).
 267. Dickson, R., Awasthi, S., Williamson, P., Demellweek, C. & Garner, P. Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomised trials. *BMJ* **320**, 1697–1701 (2000).
 268. O'Lorcain, P. & Holland, C. V. The public health importance of *Ascaris lumbricoides*. *Parasitology* **121**, S51–S71 (2000).
 269. de Silva, N. R., Guyatt, H. L. & Bundy, D. A. Morbidity and mortality due to *Ascaris*-induced intestinal obstruction. *Trans. R. Soc. Tropical Med. Hyg.* **91**, 31–36 (1997).
 270. Roy, K., Kundra, P. & Ravishankar, M. Unusual foreign body airway obstruction after laryngeal mask airway insertion. *Anesthesia Analgesia* **101**, 294–295 (2005).
 271. Husain, S. J., Zubairi, A. B., Sultan, N., Beg, M. A. & Mehraj, V. Recurrent episodes of upper airway blockage associated with *Ascaris lumbricoides* causing cardiopulmonary arrest in a young patient. *BMJ Case Rep.* **2009**, bcr0120091415 (2009).
 272. Prakash, S., Sitalakshmi, N., Singh, J., Dayal, M. & Gogia, A. R. *Ascaris*: an unusual cause of airway obstruction during general anesthesia with ProSeal laryngeal mask airway. *J. Anaesthesiol. Clin. Pharmacol.* **30**, 298–300 (2014).
 273. Endara, P. et al. Effect of urban vs. rural residence on the association between atopy and wheeze in Latin America: findings from a case-control analysis. *Clin. Exp. Allergy* **45**, 438–447 (2015).

274. Caraballo, L., Acevedo, N. & Zakzuk, J. Ascariasis as a model to study the helminth/allergy relationships. *Parasite Immunol.* **41**, e12595 (2019).
275. Dunn, J. C. et al. A cross-sectional survey of soil-transmitted helminthiasis in two Myanmar villages receiving mass drug administration: epidemiology of infection with a focus on adults. *Parasites Vectors* **10**, 374 (2017).
276. Asbjørnsdottir, K. H. et al. Assessing the feasibility of interrupting the transmission of soil-transmitted helminths through mass drug administration: the DeWorm3 cluster randomized trial protocol. *PLoS Negl. Trop. Dis.* **12**, e0006166 (2018).
277. Anderson, R. M., Turner, H. C., Truscott, J. E., Hollingsworth, T. D. & Brooker, S. J. Should the goal for the treatment of soil transmitted helminth (STH) infections be changed from morbidity control in children to community-wide transmission elimination? *PLoS Negl. Trop. Dis.* **9**, e0003897 (2015).
278. Pullan, R. L. et al. Effects, equity, and cost of school-based and community-wide treatment strategies for soil-transmitted helminths in Kenya: a cluster-randomised controlled trial. *Lancet* **393**, 2039–2050 (2019).
279. Becker, S. L. et al. Toward the 2020 goal of soil-transmitted helminthiasis control and elimination. *PLoS Negl. Trop. Dis.* **12**, e0006606 (2018).
280. Hollingsworth, T. D., Truscott, J. E. & Anderson, R. M. in *Ascaris: the Neglected Parasite* (ed. Holland, C.) 231–262 (Elsevier, 2013).
281. Jex, A. R. et al. *Ascaris suum* draft genome. *Nature* **479**, 529–533 (2011).
282. Coghlan, A. et al. Comparative genomics of the major parasitic worms. *Nat. Genet.* **51**, 163–174 (2019).
283. Kaminsky, R. et al. A new class of anthelmintics effective against drug-resistant nematodes. *Nature* **452**, 176–180 (2008).
284. Partridge, F. A. et al. An automated high-throughput system for phenotypic screening of chemical libraries on *C. elegans* and parasitic nematodes. *Int. J. Parasitol. Drugs Drug. Resistance* **8**, 8–21 (2018).
285. Yemini, E., Jucikas, T., Grundy, L. J., Brown, A. E. & Schafer, W. R. A database of *Caenorhabditis elegans* behavioral phenotypes. *Nat. Methods* **10**, 877–879 (2013).
286. Partridge, F. A. et al. Dihydrobenz[e][1,4]oxazepin-2(3H)-ones, a new anthelmintic chemotype immobilising whipworm and reducing infectivity in vivo. *PLoS Negl. Trop. Dis.* **11**, e0005359 (2017).
287. Partridge, F. A. et al. 2,4-Diaminothieno[3,2-d]pyrimidines, a new class of anthelmintic with activity against adult and egg stages of whipworm. *PLoS Negl. Trop. Dis.* **12**, e0006487 (2018).
- This paper reports the discovery of a novel anthelmintic compound with activity against both adult *Trichuris* spp. parasites and the parasitic egg stage and discusses the potential for environmental control to break the parasite life cycle.**
288. Mejer, H. & Roepstorff, A. in *Proc. 23rd International Conference of the World Association for the Advancement of Veterinary Parasitology* 113 (International Conference of the World Association for the Advancement of Veterinary Parasitology, 2011).
289. Tilney, L. G., Connelly, P. S., Guild, G. M., Vranich, K. A. & Artis, D. Adaptation of a nematode parasite to living within the mammalian epithelium. *J. Exp. Zool. Part. A, Comp. Exp. Biol.* **303**, 927–945 (2005).
290. Lee, T. D. & Wright, K. A. The morphology of the attachment and probable feeding site of the nematode *Trichuris muris* (Schrunk, 1788) Hall, 1916. *Can. J. Zool.* **56**, 1889–1905 (1978).
291. Glover, M., Colombo, S. A. P., Thornton, D. J. & Grecis, R. K. Trickle infection and immunity to *Trichuris muris*. *PLoS Pathog.* **15**, e1007926 (2019).
292. Abolins, S. et al. The comparative immunology of wild and laboratory mice, *Mus musculus domesticus*. *Nat. Commun.* **8**, 14811 (2017).
293. Leung, J. M. et al. Rapid environmental effects on gut nematode susceptibility in rewilded mice. *PLoS Biol.* **16**, e2004108 (2018).
294. Vercruysse, J. et al. Is anthelmintic resistance a concern for the control of human soil-transmitted helminths? *Int. J. Parasitol. Drugs Drug Resistance* **1**, 14–27 (2011).
295. Diawara, A. et al. Association between response to albendazole treatment and β -tubulin genotype frequencies in soil-transmitted helminths. *PLoS Negl. Trop. Dis.* **7**, e2247 (2013).
296. Ronéus, O. Studies on the aetiology and pathogenesis of white spots in the liver of pigs. *Acta Veterinaria Scandinavica* **7** (Suppl 16), 1–112 (1966).
297. Urban, J. F. Jr. & Tromba, F. G. An ultraviolet-attenuated egg vaccine for swine ascariasis: parameters affecting the development of protective immunity. *Am. J. Veterinary Res.* **45**, 2104–2108 (1984).
298. Tsuji, N. et al. Intranasal immunization with recombinant *Ascaris suum* 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to *A. suum* infection in mice. *Infect. Immun.* **69**, 7285–7292 (2001).
299. Wei, J. et al. Yeast-expressed recombinant As16 protects mice against *Ascaris suum* infection through induction of a Th2-skewed immune response. *PLoS Negl. Trop. Dis.* **11**, e0005769 (2017).
300. Versteeg, L. et al. Protective immunity elicited by the nematode-conserved As37 recombinant protein against *Ascaris suum* infection. *PLoS Negl. Trop. Dis.* **14**, e0008057 (2020).
301. Briggs, N. et al. *Trichuris muris* whey acidic protein induces type 2 protective immunity against whipworm. *PLoS Pathog.* **14**, e1007273 (2018).
- The authors identify the *Trichuris muris* whey acidic protein as a promising human vaccine candidate.**
302. Zawawi, A. et al. In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection. *PLoS Pathog.* **16**, e1008243 (2020).
303. Khurana, S. & Sethi, S. Laboratory diagnosis of soil transmitted helminthiasis. *Tropical Parasitol.* **7**, 86–91 (2017).
304. Lamberton, P. H. & Jourdan, P. M. Human ascariasis: diagnostics update. *Curr. Tropical Med. Rep.* **2**, 189–200 (2015).
305. Knopp, S. et al. A single FLOTAC is more sensitive than triplicate Kato-Katz for the diagnosis of low-intensity soil-transmitted helminth infections. *Trans. R. Soc. Tropical Med. Hyg.* **103**, 347–354 (2009).
306. Cools, P. et al. Diagnostic performance of a single and duplicate Kato-Katz, Mini-FLOTAC, FECPAKG2 and qPCR for the detection and quantification of soil-transmitted helminths in three endemic countries. *PLoS Negl. Trop. Dis.* **13**, e0007446 (2019).
307. Levecke, B. et al. A comparison of the sensitivity and fecal egg counts of the McMaster egg counting and Kato-Katz thick smear methods for soil-transmitted helminths. *PLoS Negl. Trop. Dis.* **5**, e1201 (2011).
308. Shiraho, E. A. et al. Development of a loop mediated isothermal amplification for diagnosis of *Ascaris lumbricoides* in fecal samples. *J. Parasitol. Res.* **2016**, 7376207 (2016).
309. Holt, D. C. et al. Soil-transmitted helminths in children in a remote aboriginal community in the Northern Territory: hookworm is rare but Strongyloides stercoralis and *Trichuris trichiura* persist. *Trop. Med. Infect. Dis.* **2**, 51 (2017).
310. Briolat, E. Worming it out. *MRC* <http://www.bpod.mrc.ac.uk/archive/2016/9/13> (2018).
311. Arnold, M., Alves, J. & Plessis, J. in *ABC of Pediatric Surgical Imaging* (eds Andronikou, S., Alexander, A., Kilborn, T., Millar, A. J. W. & Daneman, A.) (Springer, 2010).
312. Yetim, I. et al. Rare cause of intestinal obstruction, *Ascaris lumbricoides* infestation: two case reports. *Cases J.* **2**, 7970 (2018).
313. O'Sullivan, J. D. B., Cruickshank, S. M., Starborg, T., Withers, P. J. & Else, K. J. Characterisation of cuticular inflation development and composition in *Trichuris muris* using correlative X-ray computed tomography and electron microscopy. *Sci. Rep.* **10**, 5846 (2020).
314. Mayer, J. U. et al. Different populations of CD11b(+) dendritic cells drive Th2 responses in the small intestine and colon. *Nat. Commun.* **8**, 15820 (2017).
315. Luda, K. M. et al. IRF8 transcription-factor-dependent classical dendritic cells are essential for intestinal t cell homeostasis. *Immunity* **44**, 860–874 (2016).
316. Gold, M. J., Antignano, F., Hughes, M. R., Zaph, C. & McNagny, K. M. Dendritic-cell expression of Ship1 regulates Th2 immunity to helminth infection in mice. *Eur. J. Immunol.* **46**, 122–130 (2016).
317. Owyang, A. M. et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. *J. Exp. Med.* **203**, 843–849 (2006).
318. Taylor, B. C. et al. TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. *J. Exp. Med.* **206**, 655–667 (2009).
319. Hopwood, T. W. et al. The circadian regulator BMAL1 programmes responses to parasitic worm infection via a dendritic cell clock. *Sci. Rep.* **8**, 3782 (2018).
- The authors provide evidence for an increased susceptibility of mice to *Trichuris muris* infection if the infection is given at night rather than day; they also show that this time of day dependency of the outcome of infection involves a molecular clock within the dendritic cells.**

Acknowledgements

The authors thank R. Forman, J. O'Sullivan and H. Smith (Lydia Becker Institute for Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK) for providing images and design of Fig. 3 and Fig. 6. The authors also thank J. O'Sullivan for design of Fig. 4. The authors acknowledge the Engineering and Physical Science Research Council (EPSRC) for funding the Henry Moseley X-ray Imaging Facility through grants (EP/F007906/1, EP/F001452/1, EP/I02249X, EP/F028431/1 and EP/M022498/1 and platform grant EP/M010619/1) within the Henry Royce Institute.

Author contributions

Introduction (K.J.E. and C.V.H.); Epidemiology (P.J.C., L.L.B., S.O.A. and O.A.S.); Mechanisms/pathophysiology (K.J.E., R.K.G., C.V.H., R.T.F. and L.L.B.); Diagnosis, screening and prevention (P.J.C., L.L.B., S.O.A., O.A.S. and R.T.F.); Management (J.K., S.O.A. and O.A.S.); Quality of Life (P.J.C., S.O.A. and O.A.S.); Outlook (D.B.S. and C.V.H.); Overview of Primer (K.J.E.).

Competing interests

All authors declare no competing interests.

Peer review information

Nature Reviews Disease Primers thanks A. Clements, A. Loukas, J. Urban and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2020